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ABSTRACT 
Introduction Cancer is affecting a growing number of persons. Still, the treatment and 
survival of cancer is improving. Radiation therapy is used in the treatment of cancer. 
Late radiation-induced injuries afflict 5–15% of irradiated patients. The urinary bladder 
and bowel may be affected after irradiation of cancer in the pelvic region. Symptoms can 
be severe, with impaired health related quality of life (HRQoL). Hyperbaric oxygen 
therapy (HBOT) involves breathing oxygen at high ambient pressure. HBOT can reverse 
radiation-induced injuries, alleviate patient-perceived symptoms, and improve HRQoL. 
We aimed to clarify the effects of HBOT on late radiation-induced injuries in the urinary 
bladder and bowel, and to clarify some of the underlying mechanisms through which 
HBOT exerts its effects. 
Methods A prospective cohort study assessed effects of HBOT on patient-perceived 
symptoms (Paper I). A rat study assessed reversal of radiation-induced stress with HBOT 
(Paper II). A methodological experiment assessed reversal of HBOT on cellular death 
induced by radiation (Paper III). A multi-center, randomized, controlled trial assessed 
patient-perceived symptoms, HRQoL, and objective clinical outcomes (Paper IV).  
Result HBOT can alleviate patient-perceived symptoms, reduce objective findings, and 
improve HRQoL in patients affected by late radiation-induced injuries (Paper I, IV). 
Oxidative stress and downstream effects, induced by the irradiation, can be reversed by 
HBOT (Paper II). Paper III outlines a method for studies on urothelial cells exposed to 
radiation and HBOT.  
Conclusion HBOT can reduce radiation-induced oxidative stress and inflammatory 
response. HBOT can reverse injuries induced by radiation therapy to the pelvic region, 
alleviate patient-perceived symptoms and lead to improved HRQoL. 
Keywords: Hyperbaric oxygen treatment, hyperbaric oxygen, late radiation-induced 
injury, cystitis, proctitis, reactive oxygen species, radiation therapy, quality of life 
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SAMMANFATTNING PÅ SVENSKA 
Risken att drabbas av cancer ökar med åldern och med ökande medellivslängd 
drabbas allt fler av cancer under sitt liv. Cancer är den främsta dödsorsaken i 
välbärgade länder som Sverige. Cancerbehandlingen blir samtidigt mer effektiv 
och fler personer lever allt längre efter att ha genomgått behandling mot cancer.  
Cancer kan behandlas på flera olika sätt, beroende på tumörens lokalisation, 
allvarlighetsgrad och individuella faktorer. Ett vanligt sätt att behandla cancer på 
är genom strålning. Denna behandling kan ge upphov till biverkningar som kan 
bli symptomgivande flera år efter avslutad behandling. Sena biverkningar 
uppkommer till följd av skador på celler orsakade av fria syreradikaler. Dessa 
skador leder bland annat till kronisk inflammation, minskad kärlförekomst, med 
åtföljande lägre syrgasnivåer och ökad bindvävsomvandling av vävnaden.  
Denna avhandling fokuserar på sena biverkningar efter strålbehandling mot cancer 
i bäckenregionen. Prostatacancer är den vanligaste cancerformen hos män. 
Gynekologisk cancer är vanligt förkommande hos kvinnor. Därtill kommer cancer 
i urinvägar och ändtarm som drabbar bägge könen. Prostatacancer drabbar ofta 
äldre män, medan de kvinnliga cancerformerna ofta drabbar personer i yngre 
åldrar. Fler förväntade levnadsår efter strålbehandling leder till att de som drabbas 
av sena biverkningar får leva fler år med sina besvär. Besvären blir vanligen mer 
och mer uttalade med åren.  
Sena biverkningar efter strålbehandling av cancer i bäckenregionen inkluderar 
besvär från urinblåsan, ändtarmen och könsorganen. Av de som strålas mot cancer 
i bäckenregionen drabbas cirka 5–15% av uttalade besvär med stor inverkan på 
deras dagliga liv. Symtom från urinvägar och ändtarm inkluderar blödningar, täta 
trängningar, smärta, läckage och urinvägsstopp. I allvarligare fall kan framförallt 
blödningar göra att urinblåsan eller ändtarmen måste avlägsnas kirurgiskt.  
Hyperbar syrgasbehandling är syre givet under tryck som är högre än det normala 
omgivande trycket. Denna behandling ges i en tryckkammare där man andas ren 
syrgas. Höga nivåer av syrgas leder till en ökad förekomst av fria syreradikaler. 
Dessa har inte någon påvisbar påverkan på frisk vävnad, men kan påverka en rad 
cellulära mekanismer i tidigare strålbehandlad vävnad. Inflammatoriskt svar kan 
dämpas eller helt släckas ut och nya blodkärl kan växa in i vävnaden.  
Föreliggande avhandling undersöker, i fyra delarbeten, effekten av hyperbar 
syrgasbehandling efter strålbehandling av cancer i bäckenregionen. Majoriteten av 
patienterna som behandlades med hyperbar syrgas upplevde symtomlindring och 
förbättrad hälsorelaterad livskvalitet, jämfört med personer som inte fick 
behandling. Djurstudier bekräftade teorierna om att hyperbar syrgasbehandling 
kan motverka biverkningar efter strålbehandling av urinblåsa. 
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DEFINITIONS IN SHORT 
Hyperbaric oxygen 
therapy 
Breathing oxygen at a higher than 
normal ambient pressure. In clinical 
practice, this usually means a partial 
pressure of oxygen of 200 kPa or 
higher. 
Radiation therapy Cancer treatment utilizing ionizing 
energy to kill cancer cells. External 
radiation often uses X-rays, but 
protons and other types of energy are 
also used. 
Brachy therapy A form of radiation therapy where a 
radioactive material is placed near 
the cancer. 
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1 INTRODUCTION 
When hyperbaric oxygen therapy (HBOT) is mentioned, most people tend to think 
about scuba diving, if anything. While this doctoral thesis explores the use of 
HBOT, it has nearly nothing to do with scuba diving. Rather, it focuses on the 
effects that a higher than normal partial pressure of oxygen may have on irradiated 
cells and tissue, as well as on overall organ function and the general health of 
patients who have undergone radiation therapy and later developed radiation-
induced injuries.  
But the story begins with a misconception. With the knowledge that some bacteria 
were killed in an environment with high levels of oxygen. Robert E. Marx et al. 
tried to treat what was perceived as deep bacterial infections causing necrosis in 
previously irradiated bone with HBOT.1 The treatment was successful, but it was 
later discovered that the necrotic areas were aseptic, i.e., the bacteria did not cause 
the necrosis, and thus HBOT did not exert its effect by killing bacteria, but rather 
through some other mechanisms.2 
How can oxygen, a molecule from the periodic system, when delivered at a higher 
than normal ambient pressure, influence cells and tissue subjected to irradiation 
therapy several years earlier? How can these effects reverse changes observed in 
affected organs and alleviate patient-reported symptoms? Indeed, the links 
between oxygen, radiation therapy, normal cells, and cancer cells are intricate. 
This thesis aims to clarify some of these links and further elucidate the role of 
HBOT in late radiation-induced injuries.  
The introduction starts with the history of HBOT and radiation therapy. This 
history is important for understanding the treatment’s role in current clinical 
practice. It continues with a description of oxygen and radical oxygen species 
(ROS), which are key actors in this thesis. The mechanisms behind the 
development of cancer, the role of radiation therapy in its treatment, and the 
mechanisms at work in the development of late radiation-induced adverse effects 
are explained. This is the scene in which this thesis is played out. The use of 
hyperbaric chambers and a general description of the indications, dosage, and 
adverse effects of HBOT will follow. Lastly, the very essence of this thesis, HBOT 
for pelvic radiation-induced injuries, is the name of the play.  
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1.1 THE HISTORY OF HYPERBARIC OXYGEN 
THERAPY AND RADIATION THERAPY 
Hyperbaric medicine usually constitutes a very marginalized part of medical 
school curricula. There is limited interest from the pharmaceutical industry in 
providing funding and supporting research in the field. Although the use of HBOT 
spans several medical specialties, it does not naturally fit into any of them. The 
hyperbaric chambers required to administer the treatment are not readily available 
and may be perceived as too costly.3 Moreover, HBOT has been used for 
indications, such as autism, multiple sclerosis, cerebral palsy, that lack scientific 
support, which may have influenced its reputation negatively.4-6 Together, this 
might explain the lack of large randomized controlled trials in the field of HBOT. 
There is, however, a long history of research in the field. A search with the term 
“Hyperbaric oxygen” in the US National Library of Medicine (2020-02-15) 
returned 10,813 papers (ncbi.nlm.nih.gov/pubmed/?term=hyperbaric+oxygen). 
The histories of HBOT and radiation therapy share some similarities. Both entered 
clinical use in the beginning of the 20th century. Both were tested on nearly all 
known medical conditions. Initially, due to a lack of solid scientific evidence, the 
respective effects of both therapies were vastly exaggerated and occasionally used 
in ways that harmed or even killed patients and sometimes even doctors and 
nurses.7 
1.1.1 ELEVATED PRESSURE  
Air pressure was first measured (with a mercury barometer) and described in the 
17th century by the Italian physicist Evangelista Torricelli.8 The first documented 
use of a hyperbaric chamber dates from the same century, to 1662, when the 
British clergyman Nathaniel Henshaw built a system to elevate and decrease air 
pressure in a closed room, which he called a domicilium.9 He claimed that acute 
conditions could be treated by elevating air pressure, i.e., hyperbaric treatment, 
and that chronic conditions could be treated by decreasing air pressure, i.e., 
hypobaric treatment.  
The lethal physiology of atmospheric pressure became apparent during the 
construction of the Brooklyn Bridge in New York in the late 1800s. Footings were 
set in riverbeds and high-pressure tunnels were built to keep the water out. 
However, such pressure also dissolved nitrogen gas molecules in the blood of 
tunnel workers. When they emerged from the pressurized conditions, the gas came 
out of solution causing a life-threatening condition: decompression sickness. This 
condition killed about one-quarter of the workers. During the building of the 
Lincoln Tunnel under the Hudson River a few years later, decompression 
chambers were used to slow depressurization. Deaths related to decompression 
sickness dropped from 25% to almost 0.10 
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1.1.2 DISCOVERY OF OXYGEN  
The Polish alchemist Michael Sendivoguis identified a substance in the air that he 
called “cibus vitae” (life’s food) as early as 1604.11 However, it took another 
century for oxygen to be described in a distinctive way, one that historically 
defined its true discovery. The English chemist Joseph Priestly and the Swedish 
pharmacist Carl William Scheele both discovered and described oxygen. Scheele 
conducted his experiment in 1772, but he did not publish it until 1777.12 Priestly 
made and published his experiment in 1774.13 The term oxygen (from Greek ὀξύς 
(oxys), meaning acid and -γενής (-genēs) meaning producer) was coined a few 
years later by Antoine Lavoisier, a French chemist.14 
It took over a century from the discovery of oxygen for it to be implemented for 
clinical use in medicine. The lack of a technique to concentrate and store oxygen 
were the main reasons for this delay. The first documented administration of 
oxygen in a clinical setting was to a patient with pneumonia in 1885.15  
1.1.3 HYPERBARIC CHAMBERS IN MEDICAL USE 
In the 1830s, a few hyperbaric chambers were built. These early chambers used 
ambient air and were called “pneumatic chambers” or “compressed air baths”. 
Hyperbaric chambers flooded with oxygen had already been tested at this time. 
Apart from the danger of handling oxygen and the risk of fires and explosions, 
reports stated that oxygen was toxic, causing convulsions and death, in 
concentrations of 300–500 kPa.16 This halted the advancement of hyperbaric 
oxygen treatment for another half century.  
The French physician Victor-Théodore Junod reported that hyperbaric therapy 
resulted in increased circulation in internal organs and the “production of feelings 
of well-being” as well as increased general health.17 Junod treated conditions such 
as tuberculosis, cholera, deafness, and menorrhagia, and he reported successful 
results in many of these conditions.18  
In 1872, Paul Bert, a French scientist, engineer, and physician, published La 
Pression Barometrique, in which he described the physiological effects of air 
under increased and decreased atmospheric pressure. In 1885, C. Theodore 
Williams published his “Lectures on the Compressed Air Bath and its Uses in the 
Treatment of Disease” in the British Medical Journal. He described the use of 
atmospheric air under different atmospheric pressures to treat diseases. He stated 
that this therapy was among the most important advances in modern medicine and 
expressed astonishment that it had thus far been ignored. 
At the end of the 19th and beginning of the 20th century, several larger hyperbaric 
chambers were built. Some were even used as hotels or spas, and hyperbaric 
medicine was marketed as “the universal treatment of all disease.”19 Other 
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chambers were used as operating rooms, and still others were used as hospital 
rooms, predominately for patients with pulmonary disease. 
It was in one of these chambers, in Lawrence, USA, that Orville J. Cunningham 
first treated patients with influenza during the late 1920s. He reported great 
improvements for these patients, especially those who had been admitted in a 
cyanotic or comatose state.20 The chamber was, however, abruptly closed after a 
mechanical failure caused the complete loss of pressure, killing all the admitted 
patients. 
 
Figure 1. Cunningham Sanitarium, a 65-foot steel sphere, with a capacity of 40 
patients. It used compressed air, not pure oxygen. It was in use for just over a decade 
before it was dismantled and scrapped.  
Image Courtesy of Cleveland State University. Michael Schwartz Library. Special Collections. 
Cunningham believed that anaerobic infections played a central role in the 
development of cancer, syphilis, hypertension, diabetes, and many other diseases. 
He was also convinced that hyperbaric medicine could eradicate anaerobic 
bacteria and hence cure many major diseases.20 Thus, he persisted in his work, 
building the largest hyperbaric chamber in the world in 1928. Situated in 
Cleveland, Ohio, USA, this hyperbaric hotel was five stories high, and each room 
was fully furnished (Figure 1). Cunningham was, however, reluctant to publish 
any scientific evidence on the medical effects of the treatment. The American 
Medical Association demanded proof, but when they failed to receive it, they made 
the following announcement: “Under the circumstances, it is not to be wondered 
that the Medical Profession looks askance at the 'tank treatment' and intimates 
that it seems tinctured much more strongly with economics than with scientific 
medicine.”21 After just a decade, the chamber was closed and later dismantled. 
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1.1.4 DIVING MEDICINE PAVED THE WAY 
In parallel with the dangers of tunnel work, the risk of developing decompression 
sickness is a major concern in relation to underwater activities, where the pressure 
is also elevated. Navies around the world have used hyperbaric chambers to treat 
decompression sickness. This condition occurs when the ambient pressure is 
decreased, thus causing gas dissolved in the tissue to be released in the same 
manner as when a bottle of carbonated liquid is opened. If the pressure of the gas 
is high enough, it can be released from the solution and form bubbles that may 
occlude blood flow or exert pressure on nerves and other tissues. If the patient is 
recompressed, i.e., the ambient pressure is increased again, e.g., in a hyperbaric 
chamber, then the gas will be forced back into the solution and the bubbles will 
disappear.  
Another concern in relation to underwater activities is aforementioned oxygen 
toxicity. Although Dräger had already constructed pressurization protocols with 
tolerable levels of oxygen in 1917, it took another 20 years before these protocols 
were implemented in clinical practice. In 1937, Albert Richard Behnke and Louis 
Shaw, two physicians working for the US Navy, administered the first hyperbaric 
oxygen treatment to a patient suffering from decompression sickness.22 
1.1.5 HYPERBARIC OXYGEN THERAPY IS BORN 
Alvaro Ozorio de Almeida was the first to use HBOT for conditions other than 
diving-related injuries. He treated leprosy, cancer, and gas gangrene during 1934–
1941.23At the beginning of the 1950s, a Dutch cardiac surgeon, Ite Boerema, 
conceived the idea of flooding the body with oxygen before cardiac and pulmonary 
surgery. After a few successful operations on animals, he convinced the University 
of Amsterdam to build a large operating hyperbaric chamber.23,24 Boerema 
performed successful cardiac and pulmonary surgery in the chamber for two 
decades, and similar chambers were built in Sydney, Boston, and in many other 
university hospitals. These hyperbaric operating chambers gradually became 
obsolete when techniques for extracorporeal circulation were developed.  
Boerema also published a paper called “Life Without Blood,” in which he 
demonstrated that life could be sustained practically without any hemoglobin, if 
the levels of dissolved oxygen in plasma were sufficiently high.25 This could be 
achieved by the administration of HBOT. In 1961, Boerema also successfully 
treated clostridial myonecrosis (gas gangrene) with HBOT, thus illustrating the 
bacteriocidic effect of high levels of oxygen on anaerobic bacteria.26 Boerema has 
been credited with the title, “Father of modern-day hyperbaric medicine.”27 
Churchill-Davidson, from Great Britain, performed a series of experiments on 
humans that involved the application of HBOT to increase the sensitivity of 
Hyperbaric oxygen treatment for pelvic radiation-induced injuries 
6 
malignant tumors to radiation therapy.28 Radiation therapy was conducted through 
a window in the hyperbaric chamber, and the patients were heavily sedated to 
prevent oxygen toxicity-induced seizures.29 In 1966, Churchill-Davidson 
summarized his work, concluding that “Early treatment results are extremely 
encouraging.”30 In later studies, a few cancer types, such as glioblastoma and 
sarcoma in the head and neck region, were treated with a combination of the two 
therapies, leading to reduced mortality and fewer recurrences of cancers compared 
to radiation alone.31 However, adverse events and late radiation-induced injuries 
were more common for patients who have received combined therapy.31 There 
were also great risks involved with administrating radiation to sedated patients in 
a hyperoxic environment, e.g., fires and explosions, aspiration of gastric content, 
and convulsions. Hence, the combination of the two therapies never became 
widespread.23 More recent research in this area are summarized in “Hyperbaric 
oxygen therapy and cancer—a review”.32 
The fact that HBOT could act as an antibiotic agent led the oral and maxillofacial 
surgeon Robert Marx to explore whether HBOT could be used to treat 
osteoradionecrosis.1 This condition predominantly develops after radiation 
therapy for cancer in the orofacial area and was once believed to be partly caused 
by chronic bacterial infection.33 In 1981, Marx et al. showed that HBOT improved 
osteoradionecrosis, but paradoxically, he also showed that the condition was not 
caused by chronic infection. Osteoradionecrosis is an aseptic necrosis caused by 
radiation, with hypoxic-hypovascular-hypocellular tissue and, eventually, chronic 
non-healing wounds.2  
The new causality of osteoradionecrosis called for another explanation for why 
HBOT seemed to be beneficial for treating this condition. Marx continued his 
work and published a number of reports during the early 1980s.1,2,34-38 He showed 
that HBOT stimulates the growth of new blood vessels in previously irradiated 
and necrotic bones. His findings are summarized in “A New Concept in the 
Treatment of Osteoradionecrosis,”2 a paper which paved the way for the treatment 
of late radiation-induced injuries with HBOT. More recent studies are summarized 
in section 1.6. 
1.1.6 A NEW KIND OF RAY 
It only took three years from the discovery of the so-called “X-ray” in 1896 for it 
to be clinically administered in the treatment of cancer. The unknown source of 
the ray made the German physics professor, Wilhelm Conrad Röntgen, call it 
“X-ray,” although his surname, “Röntgen,” is frequently used as a synonym.39 In 
1901, Röntgen was awarded the Nobel Prize in Physics for his discoveries. 
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Within a few years, several well-known scientists, such as Marie and Pierre Curie, 
Henri Becquerel, and Ernest Rutherford, added more knowledge to the field.40 The 
use of radiation started as a diagnostic method, utilizing electromagnetic rays in 
relatively low-voltage machines. It continued with repeated application and 
increasing voltage and with radiation from radium, with cancer being only one of 
the many conditions to which it was applied (Figure 2).41 
Figure 2. Radiation was marketed to treat all kinds of disease. “A century of x-rays 
and radioactivity in medicine: with emphasis on photographic records of the early 
years.” Francis Mould (1993).  
Public Domain: https://en.wikipedia.org/w/index.php?curid=32468063 (2019-10-05) 
For some tumors, like carcinoma and epithelioma, radiation therapy seemed to be 
much more effective than other treatment modalities, which by that time mainly 
involved surgery.226 Radium was also used to treat tuberculosis, arthritis, gout, 
sexual disorders, obesity, high blood pressure, and many other conditions.42,43 In 
the early years, the positive effects of the treatment were exaggerated, and 
radiation therapy was marketed as the “universal treatment of all disease.” The 
most famous “Radium SPA Hotel” was in St. Joachimsthal, where radon 
inhalation rooms and baths were available. 
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Without any other means to measure the radiation dose, radiologists tested 
radiation beams on their own arms. A dose that produced a pink skin reaction 
(erythema) was considered an optimal dose. Many of these radiologists later died 
of leukemia. The paradoxical finding that radiation therapy could not only cure 
cancer but also cause it launched (ongoing) efforts to refine the therapy and 
minimize its adverse effects.44,45  
With advances in the technical field and improved knowledge of radiation and the 
response of tumor cells to irradiation, it became possible to target the tumor more 
accurately. With higher precision, the efficacy of the treatment improved, and 
adverse effects became manageable. Modern radiation therapy uses high-
resolution images to map the tumor in three dimensions and target it from several 
different directions.46,47  
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1.2 OXYGEN, PRESSURE, AND REACTIVE 
SPECIES 
The word stress can be used to describe conditions of imbalance between demands 
and resources. Oxidative stress can occur when the demand for oxygen exceeds 
the available oxygen (hypoxia), triggering an array of downstream effects. 
Oxidative stress can also occur when the available oxygen exceeds the demand 
(hyperoxia), paradoxically triggering similar downstream effects. While this 
might seem like a flaw in evolution, one must remember that hypoxia is a normal 
physiological state, while hyperoxia is not. 
1.2.1 OXYGEN  
Oxygen is a highly reactive agent that needs constant replenishment by photo-
synthesis.48 Aerobic organisms use oxygen for energy production, and most 
molecules in living organisms contain oxygen, e.g., proteins, carbohydrates, fats, 
nucleic acids, teeth, and bone.  
Otto Warburg was awarded the Nobel Prize in 1931 for showing that oxygen is 
part of an enzymatic process in the mitochondria that conveys energy to the cells. 
Later, in 1938, Corneille Hayman was awarded the same prize for demonstrating 
that the levels of oxygen in the blood can be sensed by the carotid body, and that 
this sense is coupled with the regulation of breathing. In 2019, the Nobel Prize in 
Medicine was awarded to William G. Kaelin Jr., Sir Peter J. Ratcliffe, and Gregg 
L. Semenza for “their discoveries of how cells sense and adapt to oxygen 
availability,” and how this affects angiogenesis. The level of oxygen in and around 
the cell plays a fundamental role in cell function and gene expression. The 
regulation of metabolism, angiogenesis, the immune system, and the production 
of red blood cells are some examples of actions coupled with oxygen levels.49 
Consequently, oxygen is contemporaneously used as a drug in many medical 
situations in order to treat regional or general hypoxia.  
1.2.2 PRESSURE AND OXYGEN 
Atmospheric pressure varies with elevation over sea level and current weather 
conditions. The standard atmosphere is defined as 101.325 kPa (1.01325 bar, 760 
mmHg, or 14.696 psi). Pressure can be expressed as absolute pressure—in which 
case, it is measured from absolute zero = vacuum. Pressure can also be expressed 
as relative pressure—in which case, it is expressed as over or under the normal 
ambient pressure, i.e., the ambient pressure is used as a relative zero, and 
deviations from relative zero are expressed as over or under pressure.48 
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Ambient pressure decreases by around 10 kPa per 1000 meters of elevation over 
sea level. Water is denser than air, and hence the pressure is increased more rapidly 
when submerged; around 10 kPa per 1 meter of sea water. This means that the 
absolute pressure is doubled (200 kPa) at 10 meters of seawater.48 
The partial pressure of a gas is the notional pressure of that gas if it occupies the 
entire volume alone and as a measurement of the thermodynamic activity of the 
molecules of the gas. The total pressure of gases in a mixture is the sum of all their 
respective partial pressures. Gases diffuse, dissolve, and react according to their 
partial pressures. The amount of oxygen necessary for respiration, and the amount 
that is considered toxic, is thus dependent on partial pressure and not 
concentration.48 
The content of oxygen in normal air is around 21%, while 78% consists of 
nitrogen. The remainder is a mixture of several gases, such as carbon dioxide and 
inert gases. Each breath of fresh air is mixed with residual gases in the airway 
system, creating the so-called dead space ventilation. The residual gas is higher in 
carbon dioxide and humidity, and lower in oxygen. This dilution means that the 
pressure of oxygen in the alveoli is between 13–15 kPa, i.e., 6–8 kPa lower than 
in inspired air.48  
1.2.3 OXYGEN CONTENT IN BLOOD 
Gas exchange takes place in the lungs, where oxygen diffuses over the membrane 
of alveolae and into the blood. There is an additional 2-3-kPa drop in oxygen 
pressure during this passage, and the pressure of oxygen in the blood as it leaves 
the lungs is about 10–12 kPa.  
Oxygen is bound to hemoglobin and dissolved in plasma. The cells extract oxygen 
from the blood in the capillaries. The cells require a steady delivery of oxygen and 
are dependent on constant blood flow as well as a sufficient content of oxygen in 
the blood. During normal resting conditions, the oxygen content of arterial blood 
is in the range of 13–18 ml/dl. The body can compensate for lower oxygen content 
with increased cardiac output and the redistribution of blood flow, but without 
adaptation, oxygen levels lower than 8-9 ml/dl will give rise to hypoxic cells.48 
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In the human body, most oxygen is bound to hemoglobin, and only a small fraction 
is dissolved in plasma. The formula for oxygen content in arterial blood is as 
follows:  
CaO2 = (K x [Hb] x SaO2) + (0.023 x PaO2) 
CaO2 oxygen content in arterial blood 
K constant for volume of oxygen bound to 1 gram of saturated   haemoglobin (ml/g); 1.34 is used in 
these calculations  
[Hb]  concentration of haemoglobin (g/dl) 
SaO2  percentage of haemoglobin saturated with oxygen (%); 100% is used in these calculations 
0.023 solubility coefficient of oxygen in plasma (ml/dl/kPa) 
PaO2 partial pressure of oxygen dissolved in arterial blood (kPa) 
 
During normal conditions, the content of oxygen is approximately: 
1.34x13x1.00 + 0.023x12 = 17.42+0.3 = 17.45 ml/dl 
The saturation of hemoglobin is normally around 100% and can thus not be 
elevated further with additional inspired oxygen. Hence, only the oxygen 
dissolved in plasma can contribute to a higher relative pressure of oxygen in the 
tissues and cells. The content of inspired oxygen can be elevated to 100 kPa during 
normobaric conditions, which can yield an oxygen level of approximately 88 kPa 
in the alveoli. The content of oxygen will thus be:  
1.34x13x1.00 + 0.023x88 = 17.42+2.024 = 19.44 ml/dl 
HBOT is defined as breathing oxygen at higher than normal ambient pressures. 
Compared to normal breathing, the oxygen content in the blood is elevated by 
around 10% (1.7 mg/dl) when breathing 100% oxygen at normobaric pressures 
and around 30% (5.2ml/dL) during HBOT given at a 240 kPa (absolute): 
1.34x13x1.00 + 0.023x228 = 17.42+5.25 = 22.67 ml/dl 
When Boerema published his paper, “Life Without Blood,”25 he used a 300 kPa 
(absolute) and 100% oxygen, and he diluted the hemoglobin of pigs to 0.6–0.2% 
(g/l not included in the paper). The content of oxygen in the blood was thus, 
theoretically: 
1.34x2x1.00 + 0.023x288 = 2.68+6.624 = 9.30 ml/dl 
This level is above the hypoxic threshold, which means that the cells obtain 
enough oxygen necessary to survive, and hence it was proven that life could be 
sustained without nearly any hemoglobin.25  
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1.2.4 OXYGEN TOXICITY 
Renaissance physician Paracelsus noted: “All things are poison, and nothing is 
without poison, only the dose permits something not to be poisonous.” However, 
before oxygen becomes poisonous, it may create several different effects that vary 
with the dose, i.e., the amount of oxygen molecules inhaled with each breath and 
the duration of the treatment. The effects of oxygen also differ between organs and 
between normal and pathologically changed tissues and cells.  
Pulmonary fibrosis, retinopathic conditions, and renal, cardiac, and hepatic 
damage are some of the changes seen after longer periods of hyperoxia, even 
during normobaric conditions.48,50-52 Hyperoxia can give rise to vasoconstriction 
with increased workload on the part of the heart. Due to the risk of complications, 
the use of oxygen in medical emergencies and intensive care should be carefully 
titrated.53,54  
Pronounced hyperoxia can give rise to acute, adverse neurological effects, in 
which both partial pressure and duration of exposure exert toxic oxygen effects on 
the central nervous system. Symptoms include disorientation, rigidity, twitching, 
and generalized seizures, accompanied by the loss of consciousness.55 There is a 
wide intra- and interindividual variation of exposure time before the onset of 
symptoms. Partial oxygen pressures exceeding 250 kPa usually give rise to acute 
neurological symptoms, but some individuals might develop symptoms at much 
lower levels (~160 kPa).55 However, this also means that oxygen toxicity with 
seizures and unconsciousness can only occur during hyperbaric conditions. 
The effects from hyperoxia can thus occur after longer periods of exposure to 
oxygen at relatively low partial pressures, while other effects can occur after 
shorter exposure periods but at much higher partial pressures. Both these aspects, 
partial pressure and time, are integral to the development of adverse as well as 
desirable effects. 
1.2.5 REACTIVE OXYGEN SPECIES – ROS 
Reactive oxygen species (ROS) is a collective term for many different oxygen 
derivates, each of which is reactive and unstable. ROS are produced as a by-
product during normal metabolism in the mitochondria, but they can also be 
produced by many other chemical processes and external agents, such as radiation 
and hyperbaric oxygen (Figure 3).56 These short-lived molecules and atoms are 
essential for many biological processes and act as obligate second messengers, but 
they can also interfere with and have deleterious effects on normal cellular 
processes.57 The effects of ROS depend on an array of factors, such as the sites for 
ROS production, the type and amount of ROS molecules, and the levels and 
actions of counteracting systems.56  
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Figure 3. Reactive oxygen species (ROS) can be formed via exogenous or endogenous 
sources. Antioxidants neutralize ROS. Damage to lipids, proteins, and DNA might 
occur if the levels of ROS exceed the capacity of the antioxidative system. 
The intricate balance between the production and elimination of ROS in the cells 
is partly maintained via the molecules responsible for eliminating ROS. 
Antioxidant enzymes, such as superoxide dismutase one and two (SOD–1, SOD–
2), hemeoxygenase one (HO–1), glutathione (GSH), and thioredoxin (Txn), as 
well as exogenous antioxidants, neutralize ROS and uphold the so-called redox 
balance.58 Elevated ROS levels activate gene transcription factors, such as nuclear 
factor erythroid 2-related factor 2 (NRF2) and nuclear respiratory factor two alpha 
(NRF–2α). These factors interact with the antioxidant response element (ARE) in 
the cell nucleus, which leads to an upregulation of genes that encode SOD–1, 
SOD–2, HO–1, GSH, catalase, and peroxidases.56,59,60 Thus, a feedback loop is 
created, one that seeks to maintain a steady state of ROS.  
Increased levels of ROS also lead to an upregulation of activator protein-1 (AP-
1), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and 
MAP kinases.56 These also induce antioxidative responses, but more importantly, 
they change the cellular state and can induce senescence and apoptosis.61  
ROS can also activate various tumor suppressor genes, e.g., retinoblastoma protein 
(Rb), p53, phosphatase and tensin homolog (PTEN) and ROS are needed in the 
progression of the cell cycle to interact with growth factors and the tyrosine kinase 
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receptor.62 ROS regulate the expression of some inflammatory cytokines, such as 
interleukin 1 and 6 (IL-1, IL-6), tumor necrosis factor (TNF), and transforming 
growth factor beta (TGF–β).63 There is a close relationship between ROS, chronic 
inflammation, and fibrosis.63,64  
One specific condition that leads to increased oxidative stress is hypoxia.65 
Hypoxia culminates in an increase of mitochondrial ROS that activate hypoxia-
inducible factor 1-alpha (HIF-1α) and vascular endothelial growth factor (VEGF), 
which are key mediators of angiogenesis.66,67 New blood vessels aim to counteract 
the hypoxia that the cells are sensing, thus constituting a vital signal pathway.  
ROS also play a central role in cancer cells. ROS levels in cancer cells are elevated, 
mainly due to increased metabolism and mitochondrial malfunction, but also by 
some oncogenes, such as Kras and C-myc.68,69 Hypoxia may also be present in 
fast-growing tumors due to hypoperfusion, which also generates increased ROS 
production.70 Other processes, such as integrin activation and changed signaling 
in metastatic cancer, also result in increased ROS production.71  
Oxidative stress causes mutations in the DNA. One mutation that is possible to 
detect is the modified DNA base 8-Oxo-2'-deoxyguanosine (8–OHdG).72 This 
molecule can be used as a marker for the amount of oxidative stress to which a 
cell or tissue has been subjected.56  
Thus, it can be concluded that the effects of ROS on cells may be vital, beneficial, 
harmful, or detrimental depending on a multitude of factors, such as the cell type, 
the ROS involved, counteracting systems, and physiological conditions. The 
duration and level of elevation of ROS also play an important role,56 as shown in 
Figure 4.  
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Figure 4. Healthy cells control their levels of ROS via the antioxidative system. Healthy 
cells in the vicinity of tumor cells may have elevated levels of ROS due to stress, 
inflammation, and competition of oxygen and metabolites. Radiation therapy aims to 
elevate the ROS levels in the cancer cells to lethal levels. Previously healthy cells might 
also die or enter senescence.  
1.2.6 NITRIC OXIDE AND NITRIC OXIDE SYNTHASE  
Nitric oxide is also an ROS that is involved in several physiological and 
pathological processes, such as vasodilation, immunological response, 
neurotransmission wound repair, and tumor development.73 Nitric oxide is 
endogenously synthesized by nitric oxide synthases (NOS) that convert L-arginine 
to L-citrulline to nitric oxide. There are different kinds of NOS, i.e., inducible NOS 
(iNOS), endothelial NOS (eNOS), and neural NOS (nNOS).73 iNOS is controlled 
at the gene transcription level, whereas eNOS and nNOS are controlled by 
intracellular processes.74 During hypoxia, eNOS is upregulated and more nitric 
oxide is produced, which is coupled with the increased expression and activity of 
HIF–1α and VEGF.75 Nitric oxide is involved in cell recruitment and vascular 
adhesion molecule expression during angiogenesis.76 
The level of neural nitric oxide is increased during HBOT due to augmentation of 
nNOS caused by oxidative stress.77 However, the production of nitric oxide is 
reduced in the airways when exposed to high partial pressures of oxygen.78 HBOT 
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decrease iNOS activity in patients with diabetic ulcers via phosphorylation of NF–
κB subunit p65.79 However, several sessions of HBOT culminate in increased 
levels of nitric oxide in diabetic wounds, which is believed to be an important 
mediator of the effect of the treatment.80 Although the production of nitric oxide 
is not directly dependent on the availability of oxygen, it is tightly regulated via 
feedback loops, and supranormal partial pressures of oxygen induce nitric oxide-
dependent pathways involved in angiogenesis.81 
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1.3 CANCER AND RADIATION THERAPY  
1.3.1 DNA – THE GENETIC CODE 
Nearly all cells have a nucleus that contains most of the genetic code, i.e., 
deoxyribonucleic acid (DNA). These double-stranded molecules, called 
polynucleotides, are composed of two different pairs of single nucleotides: 
cytosine and guanine, and adenine and thymine. The nucleotides are stabilized by 
hydrogen bonds. Human DNA is arranged in 23 pairs of chromosomes and 
consists of around three billion base pairs. Only 1.5 percent of human DNA carries 
relevant information for protein coding; the remaining DNA is non-coding, 
although many of these sections play important roles in the regulation and 
expression of the genome.82  
1.3.2 THE CELL CYCLE 
The normal state of most cells is called the resting stage or growth stage zero (G0). 
The “resting” refers to the fact that the cell is not yet preparing to divide but is 
instead carrying out all its functions in the body. Some cell types stay in the resting 
stage for hours, others for years. The cell can enter the next stage, called G1-phase, 
in response to different growth stimuli. During this phase, the cell produces many 
proteins and molecules that will replicate the DNA. During the next phase, the S-
phase, the DNA is replicated, a process in which errors in the DNA are likely to 
occur. The last stage is the G2-phase, which take place before cell division, called 
mitosis. The G1- and G2-phases represent important checkpoints that, if they fail, 
might stop and revert the division process or even kill the cell (Figure 5).82  
Figure 5. The cell cycle contains several steps during which the DNA is replicated. 
There are several checks for errors at each step in the cycle.  
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1.3.3 DEVELOPMENT OF CANCER 
Although both intricate and advanced, cellular control and repair mechanisms are 
not able to correct all errors. Uncorrected errors are called mutations and are 
propagated down to each new generation of cells. Moreover, numerous 
extracellular agents can cause mutations in DNA, even when the cell is not 
dividing.82  
If mutations lead to impairment in the cell, it is usually sensed, and the cell 
accordingly initiates a pathway that will either lead to its own death, apoptosis, or 
prevent it from growing or dividing into new cells, senescence. If the mutations 
are more severe, the cell might not even be able to initiate apoptosis and will thus 
be killed in an uncontrolled way, called necrosis (Figure 6).82  
The cell might start dividing uncontrollably if the mutations occur in a part of the 
DNA responsible for the growth and division of the cell, or in areas that are 
responsible for the control and correction of errors. In this case, the cell will 
become a cancer cell. Most cells that develop into this dangerous state of relentless 
division are recognized as faulty by other cells, such as natural killer (NK) cells, 
macrophages, and cytotoxic T cells.  
In the rare event that all these mechanisms fail, just one cancer cell can generate 
millions of daughter cells, forming both solid tumors and circulating cancer cells 
(Figure 6). The lack of sensing and response causes the cancer cell to disregard 
external factors that would normally have halted or stopped its division, such as 
low oxygen tension or acidic conditions.82  
The severity of the cancer will depend on several factors, such as the type of 
original cell, its location in the body, the production, excretion, and expression of 
certain proteins and molecules, the speed of growth, and whether the cell respects 
normal tissue boundaries. If it does not respect these boundaries, thereby 
infiltrating other tissues and organs, the cancer cell is defined as malignant.82 The 
severity of the cancer is also highly dependent on the overall state of the body in 
which it resides. Both cancer-specific characteristics and individual factors must 
thus be considered in the treatment of cancer.83 
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Figure 6. Cells are constantly subject to damage, with as much as 500,000 DNA 
modification events per cell per day. Most of these errors are corrected, and the cell 
continues to live and divide. If unrepairable errors are detected, the cell usually kills 
itself via apoptosis, but it can also enter senescence. Cancer cells are usually detected 
and killed by other cells via autophagy, but they occasionally give rise to tumors.  
1.3.4 RADIATION THERAPY  
The treatment of cancer can be divided into three different modalities: surgical 
removal, radiation therapy, and medical treatment (predominately chemotherapy, 
hormone therapy, and immunotherapy). The common goal is to effectively destroy 
cancer cells while, at the same time, doing as little harm to the patient as possible. 
Also, it is preferable for the treatment to be as fast and inexpensive as possible.83  
There are different kinds of radiation: acoustic, electromagnetic, gravitational, 
photon, and particle. The clinical term radiation therapy refers to the use of 
particle or photon radiation with an energy level high enough to alter the state of 
other atoms, i.e., ionizing capabilities. The energy needed to classify radiation as 
ionizing is usually set to >10 eV. Examples of particle radiation include electrons, 
protons, neutrons, alpha particles, and beta particles. Photon radiation clinically 
uses X-rays and gamma rays.84  
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The energy that ionizing radiation carries can force single electrons out of their 
track around an atom, thereby leaving the atom with a net positive charge. Both 
the free electron and the atom become reactive, i.e., they disturb the stability of 
other atoms and molecules. Ionizing radiation can be directly lethal to the cell in 
higher doses, but radiation therapy is given in sub-lethal doses in order to conserve 
the healthy tissue surrounding the tumor. The presence of normal cells around the 
cancer cells limits the strength of the radiation dose that can be delivered in clinical 
practice.84 
In clinical doses, it is not the radiation beam per se that causes the most damage 
to the cells, but rather the formation of ROS that are created in its wake. These 
highly reactive molecules can cause grave damage to the DNA and to the rest of 
the cell.85 These effects are most apparent during cell division, when they can lead 
to one of three major pathways of cellular death: apoptosis, necrosis, or autophagy. 
All these pathways are dependent on ROS (Figure 7).61,86,87  
Figure 7. Irradiation can give rise to direct cellular death. In clinical doses, most 
cancer cells are killed via indirect effects mediated via ROS: ROS also initiates several 
effects in previously healthy cells, such as elevated oxidative stress and chronic 
inflammation. 
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1.4 RADIATION-INDUCED INJURIES 
The risk of developing cancer increases with age; at the same time, life expectancy 
is increasing in most countries. Although the incidence rates of some forms of 
cancer are declining, in general, an increasing number of persons are being 
diagnosed with cancer. Consequently, a growing number of people will also 
undergo cancer treatment during their lifetime.88 Fortunately, cancer treatments 
are becoming increasingly effective, with the five-year mortality rate falling to 
under 30% in wealthier parts of the world.89 Paradoxically, with improved 
treatment for other diseases, such as cardiovascular diseases, cancer has become 
the leading cause of death in wealthy countries.90  
At least 50% of cancer-treatment regimens include radiation therapy. 
Improvements in the administration of radiation therapy have led to a reduction in 
its adverse effects.89 However, with a lower incidence of adverse effects, radiation 
doses have been increased for some forms of cancer in order to maximize the effect 
of the treatment.91 Although the incidence of radiation-induced injuries is 
gradually decreasing, the prevalence of such injuries appears to have remained the 
same or may have even increased, since people are living longer, suffering from 
more types of cancer, and surviving for longer periods after their treatments.  
The adverse effects of radiation therapy can be divided into acute and late, where 
the former is self-limiting, and the latter is chronic. Acute adverse effects may 
occur during radiation therapy and can be both local and systemic, causing 
symptoms from organs adjacent to the tumor and general symptoms, such as 
fatigue and nausea. These acute effects are mainly due to massive cellular death 
and subsequent reactions in the radiated area. When cells are killed, the body must 
break down and dispose of the residuals. This process is mainly carried out by 
different cells in the immune system and necrotic cells promote inflammation. 
Radiation therapy initiates an immune response that causes inflammation, the 
release of inflammatory cytokines, and the involvement of other systemically 
active agents that cause both local and systemic reactions.92  
The most common manifestation of late radiation injuries are symptoms emerging 
or persisting for six months following radiation therapy.93 The onset of late 
radiation-induced injuries has been reported to occur as late as 20 years from the 
radiation event, while the median time has been reported to be around three 
years.94,95  
Many non-cancerogenic cells that are subjected to irradiation develop mutations 
in their DNA. These cells might be hindered from dividing, since their control 
systems detect damaged DNA and prevent them from entering the G0-stage.96 
These cells may remain in the resting stage for a long period of time, performing 
normal actions but never dividing. If a substantial number of cells in the affected 
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organ are unable to divide, then the density of healthy cells will decrease over time 
as an effect of aging. One cell line that is especially sensitive to this process is the 
endothelial cell line surrounding the blood vessels.96,97 For this cell line, the blood 
supply becomes disrupted when a sufficient number of endothelial cells are 
depleted, which in turn leads to hypoxia in the tissue.98 Hypovascularity, 
hypocellularity, and hypoxia are characteristic of radiation-induced injuries, a 
condition which Robert Marx referred to as the 3-H stage.2  
Figure 8. Irradiation initiates a vicious circle with chronic inflammation and fibrotic 
healing. The levels of ROS and fibrotic factors are elevated after irradiation. This leads 
to a disruption in the basal membrane and the infiltration of fibroblasts in the 
epithelium. Blood vessels are damaged, and collagen and the extracellular matrix are 
deposited in the epithelium.  
There is a strong relationship between oxidative stress and chronic inflammation 
after radiation therapy.99 The cellular response and death induced by radiation 
therapy leads to the recruitment of immunocompetent cells, such as macrophages 
and lymphocyte T cells. These cells release several inflammatory mediators, such 
as cytokines (IL-1, IL-2, IL-6, IL-8) as well as TNF, interferon gamma (IFN-γ), 
and TGF-β.100 The release of these mediators initiates a secondary immunological 
response with the release of prostaglandins and free radicals, such as 
ROS,101which in turn leads to the recruitment of more inflammatory cells, 
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initiating a vicious circle.99 This chronic inflammatory state leads to a 
malfunctional tissue repair process, culminating in the development of fibrosis, 
the depletion of organ-specific cells, and hypoxia (Figure 8).  
Radiation is one of the few extrinsic activators of TBF–β, a cytokine involved in 
many cellular processes, such as cell proliferation and the production of the 
extracellular matrix.102 TBF–β activates Smad proteins (transcription factors), and 
the increase of Smad3 has been closely linked to the development of radiation-
induced fibrosis.103 TNF and IL-1 are pro-inflammatory and activate the secretion 
of matrix metalloproteinases (MMPs). MMPs are secreted as proenzymes that are 
activated by NO, oxygen and plasmin. MMPs can degrade the extracellular matrix 
and basal membranes, thus increasing fibrosis.104 
The pathogeneses of adverse effects are similar in different organs, but the 
symptoms may differ depending on the organ affected. Fibrosis can cause 
impairment of vessel and parenchymal function since it restricts their function due 
to strangulation of all components within organs. This may result in the 
impingement of nerves or restrict passage through tubular organs, such as the 
urethra, trachea, intestines, or esophagus. Other organs, such as the urinary 
bladder, lungs, and heart, might have their volume or movement restricted due to 
fibrosis. The skin and other superficial tissues lose their elasticity, which can cause 
ulcers and impaired wound healing. If these ulcers occur in the intestines or urinary 
bladder, they can cause intermittent or chronic hemorrhage and fistulas.105  
1.4.1 NORMAL FUNCTION OF THE URINARY BLADDER 
AND RECTUM 
The main function of the urinary bladder and the rectum is to store urine and stool, 
respectively, and to allow their irregular and controlled release. Both organs are 
highly elastic, densely innervated, and well circulated. Distention as well as 
chemical stimulation initiates the urge to void urine or pass stool, an urge that can 
be suppressed until the autonomous nervous system overrides the voluntary 
signals to hold back.106  
The epithelial lining of the urinary bladder is called the urothelium (Figure 9). It 
consists of three different levels of cells: basal, intermediate, and superficial. The 
basal cells situated just above the basal membrane are epithelial stem cells that 
provide long-term renewal of the epithelium. The intermediate cells are highly 
proliferative and can thus respond by quickly regenerating cells lost due to 
infection or injury. The superficial cells are fully differentiated and provide an 
impenetrable barrier for water, electrolytes, and other chemicals. All endothelial 
cells in these layers are connected to the basal membrane via filaments.107 
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Figure 9. Normal anatomy and histology of the urinary bladder.  
Underneath the basal membrane lies the lamina propria, followed by three 
different muscle layers. The lamina propria is filled with nerve endings, blood 
vessels, interstitial cells, fibroblasts, adipocytes, elastic fibers, and smooth muscle 
fascicles (muscularis mucosae). All layers are involved in the intricate signaling 
that regulates the distention of the urinary bladder and the urge to void. 
Disturbances in any of these layers or cell types might impair the overall function 
of the bladder, thus giving rise to an array of pathological conditions, such as 
radiation-induced injuries.108 
The distal part of the sigmoid colon and rectum share several characteristics with 
the urinary bladder. Closest to the lumen is the intestinal epithelium or mucosa, 
with simple columnar enterocytes and goblet cells. Underneath the epithelium is 
the lamina propria, which is rich in blood vessels, lymph nodes, and loose 
connective tissue. The muscularis has one inner circular and one outer longitudinal 
musculature surrounded by the serosa.106  
1.4.2 RADIATION-INDUCED INJURIES IN THE URINARY 
BLADDER  
An increased proliferation of the urothelium and damage to the tight cellular 
junctions are seen following radiation therapy.109 The normal polysaccharide layer 
is also damaged and, in combination, these effects lead to a pathologically 
increased permeability of the urothelium, allowing metabolites and bacteria to 
enter the underlying tissue.93 This altered permeability is hypothesized to play a 
major role in the development of late radiation-induced injuries.110,111 An increased 
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number of lysosomes and autophagic vacuoles are present in all cell layers, and 
multinucleate fibroblasts are seen together with edematous and necrotic 
endothelial cells.112 When assessing the mucosa directly post-radiation, a diffuse 
mucosal edema followed by vascular telangiectasia, interstitial fibrosis, and 
mucosal bleeding is observed.113  
As previously described, irradiation leads to increased oxidative stress in the 
tissue, demonstrated by elevated levels of 8–OHdG.114 Downstream effects 
include elevation of TGF–β, IL–1, TNF, and ICAM–1, all related to the 
development of fibrosis, which restricts the function of the urinary bladder.115 The 
regenerative process is impaired by the chronic inflammation, senescence, and 
malfunction of normal cells previously injured by irradiation. This may lead to 
malfunctioning revascularization with superficial and fragile blood vessels, which 
are prone to disruption and bleeding.113 These changes may progressively deplete 
the blood supply to the urothelium, giving rise to chronic ischemia.113 
1.4.3 PREVALENCE OF RADIATION-INDUCED INJURIES 
Around 60% of male and 22% of female cancer survivors (on five-year follow-up) 
had previously been treated for cancer in the pelvic region.116 Radiation therapy is 
given to around 50% of patients diagnosed with cancer, and around 40% of all 
cancers are cured with radiation therapy.117 
The most common cancer in the male population is prostate cancer, with an 
incidence of around 200 per 100,000 male residents in Sweden (10,500 new cases 
per year).116 This incidence increases with age and, with longer life expectancy, 
the incidence rate is expected to double by the year 2030.118 Radiation therapy is 
given as the only treatment to one-third of patients and as an adjunctive to radical 
prostatectomy.119 Treatment is effective, and “only” 25–20% of those diagnosed 
with prostate cancer will eventually die from the disease.119,120 Approximately 
50% of those treated for prostate cancer report bowel or urinary dysfunction to 
some degree.121 
Other forms of cancer in the pelvic region, e.g., cervical, uterine, urinary, colon, 
and rectal cancer, are also treated with radiation therapy. Together, these cancer 
types constitute nearly 20% of all cancers.116,119 Some of these cancer forms affect 
people of a younger age, with a long life expectancy after radiation treatment for, 
e.g., cervical and uterine cancer.116 Hence, the time needed for late radiation-
induced injuries to develop is longer, and those affected will therefore have to cope 
with their symptoms for longer. 
Acute symptoms from the urinary bladder are reported by 23–80% of pelvic 
irradiated patients.93 These symptoms usually subside within three to six months 
post radiation.122 The risk of developing late radiation-induced injuries depends on 
an array of factors, such as the biologically active radiation dose, the organs 
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affected, and individual sensitivity.123 The estimates of prevalence also depend on 
the diagnostic definitions used. Hence, the reported prevalence of more severe 
urinary and bowel dysfunction after radiation therapy varies greatly: 9‒21% 
following treatment of prostate cancer, 3‒7% for cervical cancer, and 2‒47% for 
bladder cancer.124 In one study 38% of women who had undergone radiation 
therapy due to cervical cancer reported chronic pelvic pain.125 Stenosis and 
dyspareunia due to fibrosis is also common.126,127 In one study, more than 30% 
were affected by bowel incontinence after radiation to the pelvic region.128 
Patients suffering from late radiation-induced cystitis and proctitis are handled by 
doctors from different specialties, e.g., general practitioners, general surgeons, 
urologists, proctologists, or oncologists. This makes it difficult to obtain a 
complete overview of the incidence and prevalence rates of these conditions. The 
incidence rate of mild to moderate injuries may also be under-reported, since many 
patients are treated conservatively. 
1.4.4 PATIENT-REPORTED SYMPTOMS  
There is a large variation in the modality and severity of symptoms between 
individual patients. However, most patients experience a symptom-free interval 
that may last for months or several years post radiation.123 The intensity of 
symptoms may vary greatly over time, but due to the progressive nature of the 
condition, these symptoms usually become more intense and persistent with 
time.93,123 
Organ-specific symptoms of the late effects of radiation to the bladder and rectum 
can be summarized as: 
 needing to pass urine/stool more often than usual (frequency) 
 pain when passing urine/stool (pain) 
 being unable to wait to empty the bladder/rectum (urgency) 
 leaking urine/stool (incontinence) 
 blood in the urine/stool (hematuria) 
 difficulty passing urine/stool 
 hard or loose stool 
 stool in urine and/or vice versa (fistula) 
These symptoms and limitations lead to reduced health-related quality of life.129 
Frequency, urgency, and incontinence all limit the patients’ ability to take part in 
normal social activities and can often lead to frequent nocturnal disturbances.129,130 
Bleeding and fistulation can lead to formation of blood cloths, which may lead to 
urinary retention and anemia, requiring catheterization or urinary deviation, blood 
transfusion, and even cystectomy in the more severe cases.131 
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1.4.5 PATIENT-REPORTED OUTCOME MEASURES 
Patient-perceived symptoms from the urinary bladder and rectum can vary in 
modality, frequency, and intensity and can affect the patient’s life differently. A 
few different questionnaires have been used to assess late radiation-induced 
injuries in the urinary bladder and rectum.  
 Late Effects Normal Tissue (LENT) Subjective, Objective, 
Management, Analytic (SOMA) scale 
 Functional Assessment of Cancer Therapy for Prostate Patients 
(FACT-P) 
 The Sexual Adjustments Questionnaire (SAQ) 
 The American Urological Association (AUA) Questionnaire 
 Expanded Prostate Index Composite (EPIC) 
The LENT/SOMA scale exists for several organ systems and is widely used. It 
mixes patient-perceived symptoms, management, and objective findings. All 
aspects are scored from zero to four or as yes/no, and a total mean value of all 
aspects is calculated. It also requires a cystoscopy to be performed on each patient. 
The scale is not constructed for use with only one section, such as patient-
perceived symptoms, and thus requires a full examination for complete scoring at 
each measuring point.132 
The FACT-P, SAQ, and AUA questionnaires have been used as standalone 
questionnaires as well as in combination. The questionnaires are comprehensive 
but focus only on male sexual dysfunction, i.e., they are not applicable for female 
subjects.133 
EPIC was originally constructed to evaluate symptoms in a male population. 
However, questions in two of the main domains are not gender-specific: urological 
and bowel. EPIC was later validated for use in a female population.134 There are 
also sexual, hormonal, and health-related quality of life domains of EPIC. The 
different domains can be used separately from each other. There are two sections 
of each domain, one with qualitative questions and one with quantitative 
questions. Answers are given on a Likert scale, i.e., answers are converted to 
numbers between 0 and 100, and means are calculated for the whole domain or for 
sub-sections assessing specific symptoms (Figure 10).  
The patient is instructed to consider an average during the past four weeks when 
answering EPIC. The quantitative questions in the urology domain are: How often 
have you leaked urine? How often have you urinated blood? How often have you 
had pain or burning with urination? Which of the following best describes your 
urinary control? (total to no control) How many adult diapers per day do you 
usually use to control leakage? The qualitative questions in the urology domain 
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are graded from “no problem” to “big problem”: How big problem, if any, has 
each of the following been for you? Dripping or leaking urine. Pain or burning on 
urination. Bleeding with urination. Weak urine stream or incomplete emptying. 
Waking up to urinate. Need to urinate frequently during the day. And finally: 
Overall, how big a problem has your urinary function been for you?  
1.4.6 CLINICAL FINDINGS 
Late radiation-induced cystitis and proctitis are both diagnoses of exclusion, 
meaning that other causes should be excluded before the patients can be diagnosed. 
Other reasons might be urinary infection, strictures, bladder stones, and cancer 
reoccurrence. Cystoscopy, an endoscopic examination of the urinary bladder, 
should be part of the examination. In more severe cases, telangiectasia, atrophy, 
erythematous mucosa, and bleeding may be seen during cystoscopy.93  
Most patients with late radiation-induced injuries lack macroscopically evident 
changes. This was illustrated by a study in which 185 men with persistent 
hematuria, previously treated with brachytherapy for prostate cancer, underwent 
endoscopic evaluation. Of these patients, 9.6% were found to have a new bladder 
tumor. Although 70.8% of the patients in this study were diagnosed with late 
radiation-induced injuries, only 7% had macroscopic findings in support of the 
diagnosis at the endoscopic evaluation.135  
1.4.7 CLINICAL OUTCOME MEASURES  
Although objective findings vary and correlate poorly to patient-perceived 
symptoms, they are of interest in the assessment of the effects of HBOT in late 
radiation-induced injuries.  
Specific classification scales are used for the clinical assessment of urinary- and 
bowel-related problems post radiation. The EORTC/RTOG classification is 
frequently used (Table 1).136 
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Bladder section of EORTC/RTOG  
Findings/ 
Grade 
0 1 2 3 4 
Micturition 
schedule 
None None Moderate 
frequency 
Severe 
frequency 
and dysuria 
Severe 
frequency 
and dysuria 
Blood 
vessels 
None Minor 
telangiectasia 
Generalized 
telangiectasia 
Severe 
generalized 
telangiectasia 
(often with 
petechiae) 
Severe 
generalized 
telangiectasia 
(ongoing 
bleeding) 
Hematuria None Microscopic 
hematuria 
Intermittent 
macroscopic 
hematuria 
Frequent 
hematuria 
Severe 
hemorrhage 
Macroscopic 
epithelial 
appearance 
Normal Slight 
epithelial 
atrophy 
Slight 
epithelial 
atrophy 
Slight 
epithelial 
atrophy 
Necrosis 
Bladder 
capacity 
>149 ml >149 ml >149 ml <150 ml <100 ml 
Table 1. EORTC/RTOG: The finding with the highest grade equals the score in the 
scale, i.e., it is not the mean value of all grades. Grade 5: Death directly related to late 
radiation effects. 
1.4.8 TREATMENT OPTIONS  
Several reviews and guidelines exist that outline the best treatment options for 
radiation-induced cystitis and proctitis.137 Mild cases are often treated 
conservatively with anticholinergic medications for frequency and urgency, 
analgesics for pain, and physiotherapy and incontinence pads for incontinence. 
While mild cases might be handled by general practitioners in primary care, more 
severe cases usually require specialist care. Radiation cystitis accounts for nearly 
10% of admissions at some urology clinics.138 Hospitalizations for radiation 
cystitis may be lengthy and costly.139 There is also a lack of awareness among 
practicing urologist regarding available treatment options.140 
Bladder irrigation with saline is usually the first-line treatment for hematuria and 
may be used to remove clots.141 Agents such as alum are used for intravesical 
fulguration. These agents cause vasoconstriction and decrease capillary 
permeability, which may lead to reduced hematuria.142,143 The efficacy and 
tolerability of intravesical alum has been reported in retrospective case series for 
several etiologies of intractable bladder hemorrhages.144,145 Success rates vary but 
have been reported to be around 60%, yet nearly 70% of these “successes” ended 
in relapse within 1.5 years.143  
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Hyaluronic acid, a mucopolysaccharide, is believed to help restore the normal 
protective layer of polysaccharides that irradiation can damage.146 Positive effects 
on bleeding as well as frequency, urgency, and pain have been reported.147,148 
Hyaluronic acid and hyperbaric oxygen had similar effects on hematuria in one 
study, with a response rate of 88–75%.149 However, only 45–50% of the patients 
were free of symptoms at follow-up 18 months post treatment.149 
There have been attempts to treat late radiation cystitis with other intravesical 
agents, such as antifibrinolytic agents, silver nitrate, and prostaglandins, but only 
in small studies and with uncertain results.109 Systemically administered agents 
have also been tried, such as estrogen, macrophage regulators (WF10), and 
tranexamic acid, but none have proven to be effective.109  
In the most severe cases, with bleedings requiring transfusions, transarterial 
embolization might be attempted. Cystectomy is the last resort and is associated 
with a high risk of morbidity and mortality. Severe complications are seen in one-
third of the patients undergoing cystectomy, and the 90-day mortality rate is 
between 4.5–16%.150,151 
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1.5 HYPERBARIC OXYGEN  
1.5.1 HYPERBARIC CHAMBERS 
A hyperbaric chamber is needed in order to administer oxygen at a higher than 
normal ambient pressure. There are several different types of hyperbaric 
chambers, but for clinical purposes, they can be divided into mono- and multiplace 
chambers. The former has room for only one patient (or a parent and a child in 
some cases; Figure 11). The oxygen is normally administered without any 
breathing system, i.e., the whole chamber is flushed with oxygen. Multiplace 
chambers have room for two or more persons (Figure 10). The oxygen is delivered 
via a breathing system, e.g., a mask placed over the mouth and nose, or a 
transparent hood with a seal around the neck. The ambient gas in the multiplace 
chamber is normal air.152  
Since monoplace chambers are flushed with oxygen, no additional respiratory 
dead space is created. In a multiplace chamber, where masks or hoods are used, 
additional dead space is created. In addition, ambient air can leak in through the 
seal of the mask or hood and further dilute the inspired oxygen. In combination, 
these effects can contribute to making the inspired partial pressure of oxygen lower 
for patients treated in multiplace chambers even when the ambient pressure is the 
same.153 This fact explains why monoplace treatment tables often utilize a lower 
total pressure compared to their multiplace counterparts, e.g., 200 kPa and 240 
kPa, respectively.152  
Figure 10. A multiplace chamber with place for several patients. 
Image copyright Kamolrat | Dreamstime.com, Image ID: 41315236 
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Figure 11. A monoplace chamber for one patient.  
Image Courtesy of Joakim Trogen, Sahlgrenska University Hospital/Östra, Göteborg, Sweden. 
Depending on the purpose and use of the hyperbaric chamber, it can be equipped 
with inlets for additional breathing gases and advanced monitoring devices. 
Modern multiplace chambers can usually accommodate patients requiring 
intensive care, e.g., when treating carbon monoxide poisoning or necrotizing 
fasciitis. Many hyperbaric chambers in hospitals are designed for a maximum 
absolute pressure of around 400 kPa. Hyperbaric chambers designed for offshore 
and diving activities can be pressurized to much higher absolute pressures.152  
1.5.2 EFFECTS OF HBOT 
Several different actions of HBOT have been observed and investigated. These 
actions, either alone or in combination, contribute to the total effect of the 
treatment for the respective indication. Hyperoxia leads to increased oxidative 
stress and supernormal levels of ROS.81 This is a key mechanism through which 
HBOT exerts some of its effects.154 
1.5.3 PHYSICAL EFFECTS 
Compression: Boyle’s law predicts that the volume of a gas is reduced when the 
pressure is elevated.155 HBOT will thus compress gas bubbles in the body and stop 
the disruption of blood flow, which may be blocked by gas emboli in smaller 
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vessels. This effect is desirable when treating decompression sickness and arterial 
gas embolism.152  
Diffusion and elimination: Henry’s law predicts that gases will dissolve in 
liquids to an extent determined by the equilibrium between the undissolved gas 
and the dissolved gas in the liquid. The diffusion gradient, i.e., the difference in 
the partial pressure of a gas, between the blood and alveoli affects the rate of gas 
exchange. Inhalation of pure oxygen at a high partial pressure leads to a steep 
diffusion gradient for nitrogen, which accelerates its elimination compared to 
simply breathing air. Nitrogen is the gas responsible for bubble formation in 
decompression sickness and arterial gas emboli.48  
Diffusion and distance: The distance to which a gas can diffuse from a capillary 
depends on the partial pressure gradient of the gas between the blood vessel and 
the tissue. The diffusion distance is increased with elevated partial pressures of 
oxygen. In cases where the blood flow is partially disrupted, e.g., diabetic foot 
ulcers, this effect can be utilized to oxygenate hypoxic tissues that would 
otherwise become necrotic.152 
Osmosis: The steep gradient of oxygen concentration between plasma and tissues 
creates an osmotic effect. The molecular diffusion of oxygen from plasma to tissue 
is coupled with a diffusion of nitrogen in the opposite direction. Together, these 
effects create a net flow of extracellular fluids from tissues to blood vessels, thus 
creating an anti-edema effect.156 In tissues in which hypoxia has already caused 
increased permeability of the blood vessels and other cellular responses that 
contribute to edema, the restoration of oxygenation may also contribute to an anti-
edema effect.157  
1.5.4 BIOCHEMISTRY 
Since oxygen is involved in an abundance of microchemical processes, increased 
oxygen levels have the potential to affect a multitude of these processes.  
Vasoconstriction: Arteries possess potassium-dependent channels that are 
activated during hypoxia. This leads to hyperpolarization and relaxation of 
vascular smooth muscle cells, which in turn causes vasodilation and increased 
blood flow.158 Hyperoxia counteracts this mechanism, and vasoconstriction is 
further enhanced by the direct effect on L-type Ca2+ channels via angiotensin II 
and the potent vasoconstrictor 20-Hydroxyeicosatetraenoic acid.157  
Reperfusion: Disruption of blood flow leads to hypoxia and subsequent damage 
to cells and tissues, eventually culminating in necrosis and cellular death. This 
process can be reversed if the blood flow is restored, but some of the inflammatory 
processes initiated by hypoxia contribute to additional tissue damage.159 Reactions 
initiated at reperfusion involve the formation of cytotoxic oxidants derived from 
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molecular oxygen. The polymorphonuclear leukocyte is a major source of reactive 
oxygen metabolites in post-ischemic tissues. Neutrophils are the primary 
mediators of the reperfusion-induced increased permeability of blood vessels.159 
An adhesion molecule, β2 integrin, is responsible for persistent adherence of 
neutrophils to the endothelium.160 If HBOT is administered before hypoxia, then 
the expression of β2 integrin is suppressed and the potential for reperfusion injury 
is significantly diminished.161-163  
Inflammation: Inflammation can be induced, modulated, and terminated via 
several different pathways depending on the underlying cause.164 Indeed, the 
resolution of inflammation is an active and tightly regulated process.165 Hypoxia 
plays an important role in inflammation.166 The inflammatory response seen in 
tissues after trauma is characterized by the release of cytokines, the activation of 
neutrophils, and enhanced microvascular adherence.167 HBOT suppresses 
inflammatory cytokines, such as TNF production, augments prostaglandin E2 
(PGE2), cyclooxygenase–2 (COX–2), and IFNγ release, and increases the anti-
inflammatory cytokine IL-10.168-170  
Angiogenesis: As previously explained, hypoxia in a cell leads to increased levels 
of ROS and increased levels of nitric oxide. One of the downstream effects is the 
increased production of angiogenetic factors, such as HIF–1α and VEGF.171,172  
The elevated production of HIF–1α and VEGF is induced by HBOT through the 
upregulation of specific genes, i.e., c-Jun, ERK, JNK, and AP–1, via ROS and 
nitric oxide activation.173 
Endothelial progenitor cells (EPCs) play a central role in angiogenesis. HBOT 
contributes to a significant increase of EPCs released from the bone marrow that 
are required to repair the hypoxic area.174 Other angiogenetic factors, such as 
angiopoietin, are also upregulated by HBOT via ROS-dependent pathways.175 
1.5.5 EFFECTS ON HOST INFECTION RESPONSE  
Hypoxia generally favors infection and impairs endogenous response.176 Infection 
contributes directly to hypoxia since microbes consume oxygen. Hypoxia is 
further aggravated by the increased demand from surrounding tissues and 
infectious response cells.177 Cells involved in infection defense, e.g., neutrophils, 
polymorphonuclear cells (PMNs), and macrophages, all utilize more oxygen. 
Neutrophils and PMNs produce ROS and superoxides and release them in the 
vicinity of bacteria in order to kill them.178 This ability is highly impaired when 
tissue oxygen levels drop below 4-5 kPa.176,179,180 Macrophage function is also 
highly impaired by low oxygen tension. Hypoxia may trigger the release of TNF, 
IL-1, and IL-8, which can adversely affect the infection response.181  
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HBOT increases tissue oxygen levels far above the lower threshold needed for 
neutrophils and PMNs to function optimally. Indeed, the function of PMNs 
reaches supranormal levels during hyperbaric oxygen conditions and kills bacteria 
more efficiently.182,183 The function of macrophages is also restored during 
HBOT.184  
Some antibiotic agents, such as gentamicin and tobramycin, are unable to 
penetrate bacteria if the oxygen tension is low. Others, such as ciprofloxacin and 
aminoglycoside, have oxygen-dependent killing effects on bacteria. The effects of 
these antibiotics are enhanced with elevated partial pressures of oxygen in the 
tissue.179,185,186  
1.5.6 EFFECTS ON BACTERIA 
Anaerobic bacteria are highly susceptible to high partial pressures of oxygen.187 
One reason for this is that such bacteria have low or no levels of SOD and are 
hence highly vulnerable to ROS.188 Oxygen acts bacteriostatically on anaerobic 
bacteria at 30 kPa and becomes bacteriocidic for strict anaerobes at oxygen partial 
pressures above 60 kPa.184  
Some bacteria, such as Clostridium perfringens, release alpha toxins that cause 
tissue injury and cellular death. High partial pressures of oxygen via HBOT 
suppress the production of these toxins and thus reduce their harmful effects. 180,189-
191 
1.5.7 WOUND HEALING 
Several different processes are involved in wound healing and recovery from 
tissue damage. Hypoxia is normal in the acute phase of injury and triggers some 
important hemostatic processes, but chronic hypoxia impairs wound healing.192 
Chronic hypoxia due to microvascular changes, and fibrosis are seen in conditions 
like diabetes mellitus and after radiation therapy.  
Collagen is an important factor in wound healing. The production and 
development of collagen are directly correlated with the partial pressure of 
oxygen. The function of several enzymes involved in cross-linking collagen and 
thus stabilizing the wound are related to the partial pressure of oxygen.193,194 The 
production of collagen is proportional to the partial pressure of oxygen up to 15 
kPa and may be further enhanced by HBOT.194-196 The differentiation of 
keratinocytes and the proliferation of fibroblasts, also involved in the stabilization 
of healing tissue and the epithelialization of the wound, are increased by HBOT.197  
Angiogenesis is important in wound healing and, as previously mentioned, HBOT 
mimics the hypoxic stress response by elevating ROS and nitric oxide with 
subsequent effects on key mediators for angiogenesis, i.e., HIF-1α and VEGF.198  
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1.5.8 HBOT IN THE CLINICAL SETTING 
While any elevation of the ambient pressure and content of oxygen in the inspired 
air will meet the definition of hyperbaric oxygen, it is only over certain levels that 
clinical effects are observed. Undersea & Hyperbaric Medicine Society (UHMS) 
defines HBOT as treatment with 100% oxygen at an absolute pressure exceeding 
140 kPa.152As with all other pharmaceutical agents, the bioactive dose and the 
duration of exposure are highly relevant factors when assessing the response.  
As previously mentioned, HBOT has been tested on an array of different 
conditions at different pressures, for varying durations and numbers of sessions. 
Preclinical studies have shown the effects of HBOT on cells, tissue, organs, and 
microbes alike, and clinical studies have shown measurable and relevant effects in 
some conditions. However, many studies are of poor quality, and HBOT is 
sometimes used for conditions for which scientific proof of effect is lacking or 
highly questionable, such as autism, cerebral palsy, and multiple sclerosis.4-6 
Oxygen can be considered a pharmaceutical drug, and some countries restrict its 
use in medical conditions, but it is also readily available without prescription and 
can be used without medical supervision, e.g., when scuba diving. Hence, non-
medical or para-medical entities can market and deliver HBOT for all sorts of 
conditions. This fact highlights the importance of separating scientifically proven 
indications from unscientific results.  
1.5.9 INDICATIONS FOR HBOT 
There are several international scientific communities devoted to hyperbaric 
medicine that have assessed available knowledge and published lists of 
“approved” indications for HBOT. The largest community, UHMS, is based in the 
US and issues such a list in collaboration with the Food and Drug Administration 
(FDA). The European Underwater and Baromedical Society (EUBS) and the 
Swedish Society for Anesthesiology and Intensive Care Medicine (SFAI) both 
have scientific reference groups for hyperbaric medicine. SFAI issues a list of 
“approved” indications for HBOT in Sweden—yet for some indications, the 
interpretation of scientific evidence differs, and hence the lists are not identical.  
SFAI states that HBOT can be considered for the following 10 conditions:199  
 Decompression sickness  
 Gas embolism 
 Carbon monoxide poisoning and fire/smoke intoxication 
 Diabetic foot ulcers 
 Late soft tissue radiation injury 
 Osteoradionecrosis 
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 Severe acute tissue ischemia 
 Necrotizing soft tissue infections 
 Intracranial abscess 
 Osteomyelitis  
1.5.10 ADMINISTRATION OF HYPERBARIC OXYGEN 
Time and pressure can be used to express the dose of oxygen delivered. However, 
it is important to understand that the pressure needs to be sufficiently high in order 
to achieve some of the desirable effects of HBOT. Longer expoure times at lower 
pressures will not compensate for this, even if the amount of oxygen delivered is 
the same. Hence, time and pressure must be assessed separately and in 
combination when assessing the dose of oxygen delivered.  
Some of the effects of HBOT are only seen when the partial pressure of oxygen 
exceeds a certain level. Boerema used 300 kPa when treating gas gangrene, but at 
this partial pressure of oxygen, toxicity is a problem.26,200 At the same time, many 
of the desirable effects described above are not seen at oxygen partial pressures 
below 160–200 kPa.37,182,195,201-204 Marx showed that HBOT, with oxygen partial 
pressures over 200 kPa, induces an upregulation of angiogenetic factors in 
previously irradiated bone, leading to increased vascular density, whereas 
normobaric oxygen (100 kPa) does not.37 
In order to compensate for the additional dead space and potential leakage when 
masks and hoods are used, Davis’ original pressurization tables for hyperbaric 
oxygen treatment in multiplace chambers used 236 kPa.200 (Actually, Davis 
originally chose 250 kPa, but since the pressure gauge was measured in feet of 
seawater (fsw), and the corresponding value (49.5 fsw) was hard to read, Davis 
backed down to 45 fsw, which corresponds to 236 kPa. Again, this is often rounded 
off to 240 kPa in chambers using pressure gauges with kPa or Bar).205  
The duration of treatment was also derived from the original work of Boerema on 
gas gangrene and was set to 90 minutes by Davis.26,200 Air brakes, in which the 
administration of oxygen is interrupted for 5–10 minutes, were introduced to 
further lower the risk of oxygen toxicity.  
For elective treatments, for which angiogenesis is one of the desired effects, Marx 
showed macroscopic signs of new blood vessels after 24 HBOT sessions.37 Later 
work has often used 30 or 40 HBOT sessions in an attempt to maximize the effect 
for these indications.206,207 However, dose-response studies in a clinical setting are 
lacking. Individual susceptibility and response to HBOT might vary, and this 
should be considered when deciding on when to terminate the treatment. One 
complicating factor is that there is a delay for some of the desired effects of HBOT 
to be clinically evident, e.g., size reduction of visible wounds and the alleviation 
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of symptoms.208 In the absence of reliable and relatively early markers of effect, 
hyperbaric clinics around the world tend to use a standardized number of treatment 
sessions for elective indications, usually between 30 to 40 treatments. 
The desired effects are different for acute indications, for which the treatment 
pressure and duration as well as the number of HBOT sessions will differ from 
those given electively. Decompression sickness is often treated at higher pressures 
(280 kPa) in order to maximize the physiological compression effect on the 
bubbles and for a longer duration (5 to 6 hours). Carbon monoxide poisoning is 
normally treated with one HBOT session, whereas necrotizing fasciitis usually 
requires several sessions during a short period of time.152 
1.5.11 ADVERSE EFFECTS OF AND CONTRAINDICATIONS 
TO HBOT 
HBOT is regarded as a safe and well-tolerated treatment with few 
contraindications.152,209 Middle-ear barotrauma, with varying degrees of bleeding 
or membrane ruptures, can occur if the patient fails to equalize pressure. While 
this injury is often mild and heals without scars, it is also preventable by guidance 
and instructions to the patient or by a small incision of the eardrum, i.e., 
myringotomy.152 Myopia, with changed vision can occur after repeated HBOT.210 
The condition is partly due to the hardening of the lens, which leads to increased 
refraction.211 However, the condition is reversible for the vast majority of 
patients.210  
Oxygen-induced seizures are extremely rare (< 1/1000 treatments) in normal 
clinical settings with the use of modern treatment tables. Such seizures are self-
terminating if the oxygen level is reduced, and patients typically recover fully from 
the event.152 
An absolute contraindication for HBOT is unventilated pneumothorax due to the 
risk of developing tension pneumothorax. Patients with pulmonary disease, such 
as chronic obstructive pulmonary disease or untreated asthma, can have unvented 
pulmonary sections (bullae) that can rupture and cause a pneumothorax during 
HBOT. Severe congestive cardiac failure can be aggravated by HBOT due to 
increased vascular resistance and increased workload for the heart. These 
conditions are relative contraindications for HBOT.152  
Severe claustrophobia might make patients reluctant to accept HBOT. 
Acculturation, sometimes with the addition of mild sedation with 
benzodiazepines, is usually enough to overcome this hurdle.152 
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1.5.12 NEW AND RECURRING CANCER AFTER HBOT 
The levels of oxygen and ROS are increased during HBOT. Theoretically, this 
could lead to the development of new cancer cells or benefit already existing 
tumors. However, the level of oxidative stress induced by HBOT alone has not 
been linked to an increased frequency of new cancers or to the stimulation of tumor 
growth, nor has it been shown to promote cancer recurrence.32,212 
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1.6 CLINICAL STUDIES ON HBOT AND LATE 
RADIATION-INDUCED INJURIES 
Late radiation-induced injuries and their treatment with HBOT have been of 
research interest for several decades, and several papers have reported favorable 
outcomes. Traditionally, soft and bony tissues are separated when assessing the 
clinical outcome of treatment in this condition. Although there are differences 
between these two types of tissue, their similarities in terms of the genesis of 
injuries as well as the effects of HBOT are apparent. For practical reasons, most 
studies focus on one organ, tissue type, or cell line, which might make it difficult 
to draw conclusions about their clinical implications. 
A health technology assessment (HTA) was made prior to the first study (Paper I) 
in order to establish the current scientific support for HBOT.213 Only controlled 
studies were considered when grading the scientific proof in this HTA report. 
Radiation-induced injuries in the urinary bladder (cystitis) were separated from 
those in the lower part of the intestine (proctitis) in this assessment. We searched 
PubMed from Jan 1, 1970 to April 5, 2011 for “cystitis” OR “proctitis” AND 
“radiation” OR “radiation injuries” [Mesh] AND “hyperbaric” OR “hyperbaric 
oxygenation” [Mesh] OR “HBO” [tiab] OR “HBOT” [tiab], limiting our results to 
the English, German, Danish, Norwegian, and Swedish languages. There was only 
one controlled, but non-randomized, study for cystitis, and one controlled and 
randomized study on proctitis. The conclusion was that there is some support for 
HBOT in radiation-induced soft tissue injuries, but there is also a clear need for 
more clinical studies.213 In a more recent systematic review, published by the 
Cochrane Library by Bennet et al., one of the main conclusions was as follows: 
“These small trials suggest that for people with LRTI [red. late radiation tissue 
injury] affecting tissues of the head, neck, anus and rectum, HBOT is associated 
with improved outcome.”137  
Listed in the HTA report, but not part of the final assessment of effect, are several 
uncontrolled and retrospective clinical trials that reported positive effects of 
HBOT for cystitis and proctitis. A positive response rate of 70–90% was reported 
in all but two of the papers.206,214-224 In the less-positive report on hemorrhagic 
cystitis, three out of eleven patients had a positive response to HBOT.225 One paper 
on proctitis reported a response rate of around 50%.226 Only a few studies have 
assessed symptoms other than hemorrhage, but these studies reported alleviation 
of frequency, urgency, incontinence, and pain from the urinary and bowel, as well 
as positive effects on health-related quality of life (HRQoL).206,220,227,228 One study 
found that early treatment, defined as the treatment of hematuria within six months 
of onset, gave a better response rate than late treatment: 27 of 28 (96%) patients 
treated early had partial or complete resolution of hematuria, while only 21 of 32 
(65%) patients treated late had similar response respectively.219 One of two 
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randomized, controlled, and blinded studies assessed the effects of HBOT for 
proctitis. It showed a significant reduction of symptoms and clinical findings 
measured with SOMA-LENT: 12.55 to 7.48 and 12.82 to 10.23, respectively; 
(p=.0019) with the number needed to treat for resolution estimated to be 3.227 The 
other randomized, controlled trial, published in 2015, showed no effect of HBOT 
when applied for chronic bowel dysfunction after pelvic radiotherapy.229 However, 
this study has been widely criticized for selection bias, employed a flawed 
evaluation method, was missing data, and was shown to have been 
underpowered.230-236  
In conclusion, a few high-quality studies have reported a positive outcome of 
HBOT for radiation-induced soft tissue injuries. Several smaller studies have also 
supported the use of HBOT for these conditions. Several preclinical papers have 
assessed the underlying mechanisms and effects that HBOT may have. The 
available knowledge lends support to several causative explanations for how 
HBOT can reverse the effects induced by radiation therapy. Many questions 
remain, however, and thus there is a need for additional studies in the field.  
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2 AIMS 
Paper I:  
Assess whether HBOT could reduce patient-perceived symptoms of late radiation-
induced cystitis and proctitis. 
Paper II:  
Assess whether radiation-induced oxidative stress reaction and subsequent 
inflammatory and pro-fibrotic response in the urinary bladders of rats could be 
reversed by HBOT, as well as whether HBOT alone triggered any response in the 
studied parameters.  
Paper III:  
Establish a cellular model for the irradiation of urothelial and endothelial cells, 
with subsequent exposure to HBOT, by assessing cell proliferation at varying 
irradiation doses and protocols for HBOT. 
Paper IV:  
Assess whether HBOT could alleviate patient-reported symptoms of late 
radiation-induced cystitis and reduce or reverse injuries in the urinary bladder in a 
randomized, controlled, multicenter trial. A secondary aim was to assess whether 
HBOT affected HRQoL.  
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3 METHODS 
The papers in this thesis range from a prospective, longitudinal cohort study (Paper 
I) via an animal model (Paper II) and a cell model (Paper III) to a clinical, 
multicenter, randomized, controlled study (Paper IV). A detailed description of 
the methods used can be found in the Methods section of the respective papers.  
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3.1 ETHICS AND APPROVALS 
Studies involving humans (Papers I and IV) were conducted in compliance with 
the International Council for Harmonization of Technical Requirements and the 
ethical principles of the Declaration of Helsinki. These studies were approved by 
the Ethics Review Board in Gothenburg, Sweden (Dnr 025-10: T108-12 and T213-
13). Paper IV was approved by the National Medical Product Agency of Sweden 
and registered in the European Union Drug Regulating Authorities Clinical Trials 
Database and in ClinicalTrials.gov. All patients were fully informed about their 
participation in the respective trials and gave their written and oral consent. Both 
papers were prepared in accordance with the Consolidated Standards of Reporting 
Trials (CONSORT) guidelines. 
The study involving animals (Paper II) was performed according to the National 
Institutes of Health guidelines for the care and use of laboratory animals and was 
approved by the Animal Ethics Committee at the University of Gothenburg (157-
2013). The paper was prepared in accordance with the Animal Research: 
Reporting of In Vivo Experiments (ARRIVE) guidelines.  
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3.2 STUDY-SPECIFIC METHODS 
3.2.1 PAPER I 
Subjects: All patients referred for HBOT with the diagnosis of late radiation-
induced cystitis or proctitis were invited to participate in the study. There were no 
additional inclusion or exclusion criteria other than the general contraindications 
to HBOT. Patients were recruited during a four-year period (Jan 2008 to Dec 
2011), and a total of 39 patients gave their consent for inclusion.  
Design: This was a prospective cohort study with an evaluation of patient-
perceived symptoms before, directly after, and six to twelve months post HBOT. 
A two-year follow-up with EPIC was also part of the design. 
Data collection: EPIC was used for the evaluation of patient-perceived symptoms. 
Patients were asked to fill in the EPIC questionnaire before the start of HBOT, 
directly after the last HBOT session, and again six to twelve months later. 
Demographic data and medical histories were collected retrospectively using a 
predefined form.  
Procedures: Patients were treated with 100% oxygen in either a multiplace 
chamber at an ambient pressure of 240 kPa or in a monoplace chamber at 200 kPa. 
Time at pressure was 90 minutes, and the treatment was given once daily, five 
days weekly. The patients initially received 30 sessions of HBOT for fewer than 
45 days before assessment for clinical response was made. Patients were 
categorized into four groups: healed, improved, unchanged, and worse, where 
“improved” patients were offered an additional 10 sessions of HBOT within two 
months of the end of the first sessions. This treatment protocol was used in the 
HORTIS-III study published in 2008 and was judged to be the best way to titrate 
the total HBOT dose.227 
Statistical analysis: The EPIC scores obtained before, during, and six to twelve 
months after HBOT were assessed for variance and analyzed using Tukey’s post 
hoc test. The mean EPIC score was compared for each specific subset of EPIC 
questions using a paired parametric 2-tailed t test.  
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3.2.2 PAPER II 
Subjects: 39 female Sprague-Dawley rats. 
Design: Rats were divided into four groups, with one group serving as the control 
and thus receiving no study-specific treatment, one group receiving radiation only, 
one group receiving HBOT only, and the last group receiving both radiation and, 
later, HBOT.  
Data collection: Analysis of mRNA was performed using q-PCR with TaqMan 
gene expression assays. Immunohistochemistry was done on paraffin-embedded 
6µm-sections. Fluorescence was measured at three representative areas and 
converted to percentages of the maximum value. The assessor was blinded to 
group allocation.  
Procedures: Radiation was given as one fraction of 20 Gy at day 1. At day 15, 
HBOT was given at 200 kPa, with 100% oxygen, for 90 minutes, bi-daily for 10 
days, totaling 20 sessions. All animals were sacrificed on day 29. The urinary 
bladder was cut into two sagittal parts, with one put in formalin for later paraffin 
embedding, and the other frozen for mRNA analysis.  
Statistical analysis: Analysis of variance (ANOVA) was used to determine 
significant differences between mean values. Tukey’s HSD post-hoc analysis 
was used for multiple comparisons between groups. 
3.2.3 PAPER III 
Cells: Human-immortalized UROtsa and HUVEC cell lines.  
Design: Cells were exposed to radiation in incremental doses (0– 20 Gy). Cell 
death and ED50 were assessed 24 hours later. Cells were then divided into four 
groups: no intervention (control), irradiation ED50 dose (radiation), HBOT 
(HBOT), and ED50 followed by HBOT (radiation + HBOT). Additionally, 
HUVEC cells were given two HBOT sessions at different time points after 
radiation. 
Data collection: The number of cells were normalized to the control, which was 
set to 100%. Number of cells were counted manually in four representative fields 
and the mean value was used for comparison between groups. 
Procedures: Cells were grown in flasks using a specific cell medium until cellular 
confluence was reached, which was defined as 100% cells in each vision field. 
One group of cells was used as the control. Two groups were irradiated using a R 
2000 x-ray irradiator at the aforementioned doses. One of the irradiated groups 
was exposed to HBOT at different time intervals. One group was only exposed to 
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HBOT. HBOT was delivered at 200 kPa using 100% oxygen for 90 minutes per 
session.  
Statistical analysis: Mann-Whitney’s test was used for comparison between 
groups and ANOVA to test for significance.  
3.2.4 PAPER IV  
Subjects: All patients between 18 and 80 years of age with late radiation-induced 
cystitis as their reason for referral were invited to participate in the study. Time 
from radiation to inclusion had to be over six months. Patients with very mild 
symptoms (EPIC total urinary score >80) were not included, nor were patients 
who had ongoing bleeding requiring blood transfusion (> 0.5L the last four 
weeks). All patients underwent cystoscopy before randomization, and patients 
were excluded if other reasons for the symptoms were found or if their urinary 
bladder capacity was under 100 ml. Also, patients requiring urinary deviation, 
such as urinary or pigtail catheters, were excluded due to the design of EPIC. 
Design: Data included patient medical history, EPIC, SF-36, clinical assessment, 
and cystoscopy with biopsies. All data were entered into an electronic case report 
form (e-CRF), where 1:1 randomization in blocks of four was done automatically. 
Stratification was done for gender (male or female), time from radiation to 
inclusion (less or more than 2 years), and previous intrusive surgery in the pelvic 
region (yes or no). Patients randomized to intervention underwent HBOT, while 
the control group continued with the previous treatment and did not receive any 
study-specific treatment.  
The evaluation of the treatment effect was done with EPIC and SF-36 directly after 
the end of the HBOT protocol for the intervention group. A safety panel of blood 
samples were also taken directly after the end of the HBOT sessions. The primary 
endpoint was assessed six to eight months post randomization during a visit that 
was identical to the screening visit. The results in the intervention group were 
compared with the results in the control group. Safety data (adverse events) were 
collected during HBOT.  
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Patients in the control group were offered HBOT after the assessment of the 
primary endpoint. All patients will be followed for five years with yearly 
assessment of EPIC and SF-36 (Figure 12). 
Figure 12. Randomization took place directly after screening (visit 1). HBOT was 
given to the intervention group (visit 2). A safety visit (visit 3) was done after HBOT. 
Visit 4 was done 6–8 months after randomization (i.e., 4–6 months after completion 
of HBOT). Visit 1 and visit 4 were identical for the two groups. 
Data collection: All data collection was performed in the e-CRF with automatic 
contingency checks and validation. Investigators and patients were asked to 
complete specific forms in accordance with the protocol. The study was monitored 
with the verification of source data, time restrictions, signatures, management, 
approvals, and other critical parameters.  
Procedures: Patients were treated with 100% oxygen in either a multiplace 
chamber at an ambient pressure of 240 kPa or in a monoplace chamber at 200 kPa. 
Time at pressure was 90 minutes and was given once daily, five days weekly, 
during 30–40 sessions.  
Cystoscopy was performed by study-specific urologists according to a 
standardized protocol. Biopsies were taken on all patients except those whom the 
urologist judged to be at high risk of bleeding or other complications. The findings 
were recorded in the e-CRF and automatically transformed to a score on the 
urinary bladder RTOG/EROTC scale. 
Statistical analysis: Sample size was calculated using the data from the pilot study 
(Paper I) and was set to 40 in each group. All data were signed and locked before 
finishing the study. The statistical analysis plan was written and signed before any 
export of data from the e-CRF-system. The difference in EPIC urinary total scores 
between the groups was tested for normality and skewness with Q–Q plots and 
kurtosis, and via statistical inference with Student’s two-sample t test. 
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4 RESULTS 
The main results from each paper are summarized in this section. The results are 
presented in full in the respective papers found in the appendix. 
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4.1 PAPER I 
During the study period (Jan 2018 to Dec 2011), 52 patients were referred for late 
radiation-induced cystitis or proctitis. Of these, 39 patients completed HBOT and 
had valid EPIC forms for evaluation (Figure 13).  
 
Figure 13. Of 52 patients reviewed for inclusion, 12 were not included, leaving 40 
eligible patients. After one dropout, 39 patients remained part of the evaluation. 
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Patient demographics and medical history 
Number of patients 39 
Age (mean) 71 (35–84) 
Sex  
   Female 4 
   Male 35 
Tumor and treatment  
      Prostate 34 
      External radiation (70-75 Gy) 23 
      Brachy therapy (28-33 Gy) 3 
      External (50 Gy) and brachy (20 Gy) 8 
      Radical prostatectomy  13 
Rectal 3 
   External radiation (25 Gy) 1 
   External (50 Gy) + chemotherapy  2 
   Rectal resection 3 
Cervix 2 
   External radiation (60-64 Gy) 2 
   Hysterectomy 1 
Table 2. Demographic and cancer treatment medical history. 
Demographic and medical histories are reported in Table 2. The mean time from 
the end of radiation therapy to urinary symptoms was 18 (range 0–120) months, 
while the mean time from the end of radiation therapy to bowel symptoms was 5.5 
(range 0–120) months. Twenty patients (51%) were affected in terms of both their 
urinary and bowel function when assessed at baseline. Nine patients (23%) had 
only urinary symptoms, and seven patients (18%) had only bowel symptoms. The 
remaining three patients (8%) had EPIC scores over 80 in both domains. The mean 
number of HBOT sessions was 36 (range 28–40). 
For all patients, regardless of symptoms, the total EPIC score at baseline was 
60.9±22.6 (n=38) for urinary and 62.2±26.5 (n=38) for bowel. The scores 
increased to 74.0±21.0 (n=37; p<.0001) urinary and 76.2±20.4 (n=36; p<.0001) 
for bowel directly after completion of the HBOT session, and remained stable at 
follow-up six to twelve months later: 73.4±23.6 (n=36; p=0.0002) for urinary and 
73.3±20.2 (n=36 p=0.0001) for bowel.  
For patients with urinary symptoms, defined as EPIC < 80 in the urinary domain, 
the total urinary EPIC score at baseline was 50.3±15.5 (n=29). The score increased 
to 65.5±18.9 (n=27; p=0.0002) directly after completion of the HBOT sessions, 
and further to 68.6±20.1 (n=27; p<.0001) compared with baseline at follow-up six 
to twelve months later (Figure 14).  
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For patients with bowel symptoms, defined as EPIC < 80 in the bowel domain, the 
total bowel EPIC score at baseline was 48.1±17.6 (n=25). The score increased to 
67.5±17.9 (n=25; p<.0001) directly after completion of the HBOT sessions and 
was 66.5±19.1 (n=25; p<.0001) compared with baseline at follow-up six to twelve 
months later (Figure 14).  
Figure 14. Total bowel and urinary EPIC scores before, directly after, and at follow-up 
6–12 months after HBOT for all patients with symptoms in the respective domain. 
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4.2 PAPER II 
The rats exposed to irradiation had an upregulation of oxidative stress marker 8-
OHdG with a mean intensity value of 34±14% (n=4) compared with 5±2% in the 
control group (n=4; p<.0001). NRF2α, SOD–2, HO-1, IL-10, and TNF were also 
upregulated by irradiation, (n=7–10; p<0.001–0.05) as shown in Figure 15, while 
TGF–β (n=7; p=0.63) and SOD–2 (n=7; p=0.58) were not.  
Rats exposed to irradiation and later to HBOT were compared with irradiated rats 
(no HBOT). 8-OHdG was restored to 11±5% (n=4; p<.0001), as were all other 
expressions elevated by radiation alone (n=7-10; p<.0001-0.05) (Figure 15). 
The rats only exposed to HBOT exhibited no significant changes compared to rats 
in the control group (Figure 15). The additional inflammatory parameters assessed, 
i.e., IL–1, IL–4, IL–5, IL–6, IL–13, and INF–γ were not affected in any group. 
Figure 15.Continued on next page 
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Figure 15. Urinary bladder expressions of mRNAs in controls (no RT, no HBOT), 
HBOT control group (no RT, HBOT), irradiated group (RT, no HBOT), and HBOT 
irradiated group (RT, HBOT), respectively (n=8–10). * indicates p<0.05 and ** 
indicates p<0.01. Vertical bars represent SEM. 
Immuno-histochemical analyses showed signs of increased oxidative stress 
predominately in the urothelium. An increase in oxidative stress was seen not only 
in the nucleus but also in the cytoplasm. SOD–2, seen in the urothelium and blood 
vessels, and OH–1, seen in the blood vessels, were increased after radiation and 
restored after HBOT (Figure 16). 
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Figure 16. Photographs of urinary bladder specimens stained for 8-OHdG, SOD-1, 
SOD-2, and HO-1 in the respective groups. Upregulation of 8-OHdG was observed in 
the urothelium in the radiation group, which was reversed by HBOT (first row). SOD-2 
was primarily upregulated in blood vessels and in the urothelium by bladder 
irradiation (third row). BV=blood vessel(s), SMC=smooth muscle cells, 
SubM=submucosa, and U=urothelium. Horizontal bars indicate 100 μm. 
Nicklas Oscarsson 
57 
4.3 PAPER III 
Irradiation induced cellular death when assessed 24 hours after irradiation. 
Effective dose 50% (ED50) was reached at 6 Gy (Figure 17).  
Figure 17. H Number of cells normalized to control (0 Gy). Number of wells counted 
per radiation dose: HUVEC n=7 UROtsa n=4-3. Standard deviation is indicated 
with whiskers, * = p<0.05, ** = p<0.01, *** = p<0.001, ns = no significance.  
Radiation caused a significant decrease in proliferation (100% to 67%, n=8, 
p=<0.0001). Irradiation followed by one session of HBOT restored the cell 
numbers to higher than initial values (128%, n=8, p=<0.0001) HUVEC cells 
exposed to one HBOT session after irradiation did not recover from cellular death 
induced by 6 Gy (Figure 18). 
Figure 18. Number of cells are normalized to control (0 Gy). Standard deviation is 
included in the box, with the whiskers indicating a 95% confidence interval, and the 
bar showing the median value, * = p<0.05, ** = p<0.01, *** = p<0.001, 
**** = p<0.0001, ns = no significance.  
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Two sessions of HBOT given at three and six hours after radiation also decreased 
cell numbers compared to only radiation. However, two sessions of HBOT given 
at three and ten hours after irradiation led to an increase in cell numbers. The same 
pattern was observed when the cells were assessed both 24 and 48 hours after 
radiation (Figure 19). 
Figure 19. Number of cells are normalized to control (0 Gy). Standard deviation is 
included in the box, with the whiskers indicating a 95% confidence interval, and the 
bar showing the median value, * = p<0.05, ** = p<0.01, *** = p<0.001, 
**** = p<0.0001, ns = no significance. 
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4.4 PAPER IV 
The study included 87 of 223 patients screened between May 9, 2012 and 
December 20, 2017. Of the patients, 42 were randomized to HBOT, and 45 
received standard care. Eight patients withdrew consent directly after 
randomization and were thus excluded from the intention-to-treat (ITT) 
population: one patient in the HBOT group, and seven patients in the standard care 
group. Hence, 79 patients were included in the ITT analyses. Group means and 
individual changes in EPIC scores are shown in Figure 20. 
Figure 20. Intention-to-treat population. (A) Changes in EPIC scores between visit 1 
and visit 4. The group mean is shown with a line, and the whiskers represent the 
5th-95th percentiles. Outliers are marked with a solid circle or square. The dotted 
line at a score of 80 indicates the cut-off for inclusion. (B) Individual changes in 
EPIC scores between visit 1 and visit 4. The patient in the standard care group who 
improved by more than 40 points unintentionally received HBOT before evaluation 
at visit 4.  
Four patients from the standard care group were excluded before visit 4. One was 
lost to follow-up, one was diagnosed with a new cancer, one died, and one patient 
was unintentionally treated with HBOT despite his group allocation. One patient 
in the HBOT group discontinued due to an adverse event. The per-protocol 
population thus included 34 patients in the standard care group and 40 patients in 
the HBOT group. 
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In the per-protocol population, the difference between changes in the group mean 
of the EPIC urinary total score at visit 4 was 11.4 points (95% CI; 3.5–19.2; 
p=0.005; 17.8 points [SD 18.4] in the HBOT group vs. 6.6 points [13.2] in the 
standard care group) (Table 3).  
Visit 1 
Baseline 
HBOT  
(n=40) 
p-value 
within 
group 
Standard 
care  
(n=34) 
p-value 
within 
group 
p-value 
between 
groups 
Difference between 
group mean (95% CI) 
Urological Total 48·0 (19·2)  42·0 (18·0)  0∙11  
Urological Function 56·0 (23·3)  48·5 (23·6)  0∙18  
Urological Bother 42·3 (19·9)  37·4 (17·1)  0∙27  
Urological 
Incontinence 
49·0 (32·9)  36·6 (28·1)  0∙091  
Urological Irr./Obstr. 49·8 (20·0)  46·4 (18·9)  0∙47  
Bowel Total 60·6 (21·2)  61·9 (23·1)  0∙81  
Visit 4 
 
HBOT 
(n=40) 
p-value 
within 
group 
Standard 
care  
(n=34) 
p-value 
within 
group 
p-value 
between 
groups 
Difference between 
group mean (95% CI) 
Urological Total 65∙5 (24∙6)  49∙0 (24∙5)  0∙0056 -10∙0 (-18∙2 to -1∙8) 
Urological Function 69∙1 (28∙8)  52∙9 (27∙3)  0∙018  
Urological Bother 62∙9 (24∙6)  46∙2 (24∙2)  0∙0056  
Urological 
Incontinence 
60∙4 (36∙7)  36∙9 (29∙9)  0∙0047  
Urological Irr./Obstr. 69∙2 (22∙7)  56∙0 (25∙0)  0∙021  
Bowel Total 73∙5 (16∙4)  67∙3 (23∙5)  0∙19  
Change from Visit 1 to 
Visit 4 
 
HBOT 
(n=40) 
p-value 
within 
group 
Standard 
care  
(n=34) 
p-value 
within 
group 
p-value 
between 
groups 
Difference between 
group mean (95% CI) 
Urological Total 17·8 (18·4) <0∙0001 6·6 (13·2) 0∙0049 0·0047 -11·4 (-19·2; -3·5) 
Urological Function 13∙8 (19∙8) <0∙0001 4·7 (14·4) 0∙070 0∙032 -9·1 (-17·3; -0·84) 
Urological Bother 20∙7 (20∙1) <0∙0001 8·0 (14·6) 0∙0031 0∙0035 -12·7 (-21·0; -4·3) 
Urological 
Incontinence 
12∙8 (18∙5) <0∙0001 0·76 (15·3) 0∙78 0∙0041 -12·0 (-20·1; -3·9) 
Urological Irr./Obstr. 19∙6 (21∙8) <0∙0001 9·0 (14·9) 0∙0014 0∙022 -10·6 (-19·4; -1·6) 
Bowel Total 13∙2 (17∙3) <0∙0001 4·1 (12·7) 0∙075 0∙017 -9·0 (-16·3; -1·7) 
Table 3. Per-protocol analyses: EPIC scores at visit 1 and visit 4, presented as means 
(SD). Differences between group means are presented together with a 95% confidence 
interval (95% CI). 
The number of patients who scored 80 or higher on EPIC at visit 4 was 16 (40%) 
of 40 in the HBOT group, and two (6%) of 34 in the standard care group. 
Mean SF-36 scores increased significantly within the HBOT group from visit 1 to 
visit 4 in four of the eight domains. Compared to the control group, the HBOT 
group improved significantly in general health (p=0.0002) and physical 
functioning (p=0.038).  
The HBOT group had higher LRMGS grades than in the standard care group at 
visit 1, but the difference was not significant (p=0∙068). At visit 4, 64% of the 
patients in the HBOT group had improved grades, 28% had unchanged grades, 
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and 8% had worsened grades. In the standard care group, 18% of the patients had 
improved grades, 53% had unchanged grades, and 29% had worsened grades 
(p=0.0012). Figure 21 depicts the intention-to-treat population.  
Figure 21. Intention-to-treat population: (A) Changes in LRMGS grades between visit 
1 and visit 4, where a lower score equals improvement and HBOT leads to a significant 
reduction compared to the control (p=0.0012). (B) Individual changes in LRMGS 
grades between visit 1 and visit 4. A lower LRMGS grade means fewer pathological 
findings.  
All patients in the HBOT group complied with the predefined protocols, and no 
dose adjustments were required. We recorded 43 adverse events affecting 17 
(41%) of 41 patients in the HBOT group: difficulty equalizing pressure in the 
middle ear (n=9), signs of barotrauma (n=4), paracentesis (n=1), transient myopia 
(n=5), Leber’s hereditary optic neuropathy (n=1; discontinued HBOT due to visual 
disturbances), and panic attack (n=1). The rest of the adverse effects were not 
classified as related to HBOT, including one serious adverse event (death due to 
sepsis and cardiac failure). 
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5 DISCUSSION 
This chapter is chronologically structured to reflect the scientific process 
discussed. The reasons for initiating the respective studies are explained along 
with the knowledge considered in their design. Also, the findings for the respective 
studies are related to previous findings and placed in context. Several questions 
were answered, but many new questions have emerged.  
5.1.1 DOES HBOT HELP AT ALL? – PAPER I 
Knowledge regarding HBOT for late radiation-induced injuries was assessed in an 
HTA report in 2012.213 HBOT seemed to be effective, but the evidence was weak. 
For proctitis, there was one randomized and controlled trial (HORTIS) that 
showed positive effects of HBOT.227  
We initiated a prospective cohort study in collaboration with the urology 
department at Shalgrenska University hospital and accepted patients with cystitis 
or proctitis for HBOT. We aimed to evaluate patient-perceived symptoms using 
EPIC. Hence, Paper I was a pilot study to evaluate not only the clinical effect of 
the treatment but also the referral and treatment protocol and the feasibility of 
EPIC for this purpose. 
Paper I indicated the alleviation of patient-perceived symptoms after HBOT for 
both proctitis and cystitis. Previous studies on radiation-induced cystitis were 
mainly focusing on hematuria.206,216-219,237 The knowledge regarding the effects on 
other symptoms and milder cases was scarce.238 Since EPIC also covers other 
symptoms, such as urgency, leakage, pain, frequency, and incontinence, Paper I 
added valuable knowledge regarding symptoms other than bleeding. Some studies 
have reported long-term data (2–5 years),225 but most studies reported one-year 
data.137 We followed our cohort for two years, and the results were stable at follow 
up.239 The lack of a control group was the major limitation in this study.  
We concluded that EPIC was a feasible instrument for the assessment of patient-
perceived symptoms. It can be used for both male and female subjects, and it 
covers both qualitative and quantitative symptoms.134 EPIC only requires input 
from the patient and can hence be used for long-term evaluation without clinical 
assessment. Furthermore, EPIC is validated and has been used for over 20 years.240 
Previous studies have reported results from healthy individuals and data on 
minimally (clinically) important differences (MID) for each domain.241-243 
5.1.2 WHO DOES HBOT HELP? 
When the individual results were assessed, some patients improved markedly, 
while others did not improve at all. With the selection of patients used in Paper I 
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and Paper IV, the responses were divided into three groups: markedly improved 
or fully recovered, improvement exceeding MID, and non-responders. Roughly, 
our results show an equal distribution of patients in each group. This raised a 
question regarding the selection of patients. One factor that might affect outcomes 
is the time from radiation to HBOT. We are aware of one study that assessed time 
as a factor.219 It assessed time from symptoms to HBOT, with a cut-off at six 
months, revealing that the effect on hematuria from HBOT was larger in the group 
that received early treatment.219 Other factors that might affect the outcome of 
HBOT are gender, age, previous surgery in the pelvic region, radiation dose, 
severity of symptoms, and pathological changes. We are not aware of any study 
that has assessed the effects on the outcomes of these confounding factors. 
Interestingly, Clarke et al. noted that non-responders may experience cancer 
recurrence or other persistent symptoms, making it important to follow-up with 
non-responders.227 
Today, there is no way to assess responses to HBOT after one or a few treatment 
sessions. The effects of HBOT might not be evident until after several weeks of 
treatment,37 and some patients only report improvement several months after the 
end of HBOT. Improved selection of patients and early assessment of effects 
would help to target the treatment to patients who respond and to avoid treating 
those who do not. 
In conclusion, HBOT seems to be effective for most patients with late radiation-
induced cystitis or proctitis, but individual responses vary. Other causes for 
patients’ symptoms should be excluded before HBOT is administered.  
5.1.3 WHY DOES HBOT HELP? 
Radiation therapy gives rise to oxidative stress with a subsequent depletion of cells 
and blood vessels, inflammation, fibrotic healing, and impaired organ function.244 
HBOT seems to counteract several of these processes and, in Paper II, we showed 
that oxidative stress is markedly reduced when HBOT is applied to the previously 
irradiated urinary bladders of rats. Paper III showed that cellular death can be 
reversed by HBOT. These findings are in line with previous reports.81,245 Blood 
vessels and cells are restored via the upregulation of angiogenetic factors such as 
HIF–1α and VEGF and the increased recruitment of stem cells.154 Most of the 
research demonstrating these changes has been conducted using animal models. 
Little is known about the histo- and biochemical changes in the human urinary 
bladder after HBOT for late radiation-induced injuries.  
HBOT leads to a fast and general elevation of ROS in the body. A slightly slower, 
but equally general response, with elevated levels of antioxidants, is also seen 
during and after HBOT. ROS fall rapidly after end of HBOT, while it takes a 
longer time to normalize the upregulated antioxidative response system. In tissue 
Hyperbaric oxygen treatment for pelvic radiation-induced injuries 
64 
with late radiation-induced injuries, inflammation and relative hypoxia leads to 
locally elevated ROS-levels. The general but temporary abundance of antioxidants 
after HBOT may be able to suppress the chronic but locally elevated ROS-levels 
in irradiated tissue. This might explain why repeated HBOT sessions eventually 
break the ROS-dependent vicious circle that radiation therapy initiated.  
5.1.4 IS HBOT BETTER THAN STANDARD CARE? – 
PROTOCOL FOR PAPER IV 
The study group that published HORTIS had initiated a double-blinded study on 
cystitis and the hyperbaric department at Sahlgrenska University Hospital /Östra 
in Gothenburg joined this study. The study was terminated prematurely.246 Low 
recruitment rate was one contributing factor. Many patients declined participation 
due to the risk of being subject to sham treatments for 6–8 weeks. Fortunately, an 
EUBS meeting was held just days after the termination of the HORTIS study. 
Representatives from all Nordic hyperbaric chambers were at this meeting, and it 
was decided that a joint study should be initiated: RICH-ART. We aimed to 
answer as many of the previous questions as possible and, at the same time, design 
a pragmatic study protocol. RICH-ART was randomized and included a control 
group. The study was stratified for gender, previous surgery in the pelvic region, 
and time from radiation to HBOT. Several potential confounding background 
factors were collected. Biopsies were taken before randomization and at the final 
assessment. A post-study five-year follow-up was included.  
RICH-ART was not blinded, since previous attempts had proven to be 
unsuccessful. The control group was offered HBOT after the final assessment in 
the study. These are limitations, but the design with late assessment may dilute the 
placebo effect that the blinding aims to counteract. Indeed, well-designed, un-
blinded, controlled studies may render equally valid outcomes as blinded studies 
and ethical issues arise when sham treatments are introduced in studies assessing 
the effects on conditions in which the treatment modality has already been 
established in clinical practice.247-249 Since HBOT initiates processes that may 
continue for months after the end of treatment, we choose to evaluate the primary 
endpoint around six months after the end of HBOT, not directly after the end of 
treatment, as Clarke et al. did. We believe that a design with a delayed assessment 
contributes to attenuating the placebo effect. Also, the expectancy before 
evaluation allowed for the natural progression of the condition in the control 
group.  
The confounding factors for which the study was stratified did not influence the 
effects of HBOT in Paper IV. The control group in RICH-ART received HBOT 
after visit 4. This means that a larger group of patients treated with HBOT were 
included in the post-study follow-up. We plan to re-assess several cofounding 
factors when the post-HBOT data are available for all patients. 
Nicklas Oscarsson 
65 
Patient-perceived symptoms, assessed with EPIC, were used as the primary 
endpoint variable in RICH-ART. EPIC is highly sensitive, and even mild 
symptoms will reduce the overall score. The study has been validated and has 
yielded data on normal values for different age groups.240 For some domains, EPIC 
scores dropped from close to 100 in lower age groups to under 90 for those aged 
over 60 years.241 We used the mean total urinary EPIC score as both a primary 
endpoint and as an inclusion variable. In using EPIC as an inclusion variable, we 
sought to exclude patients with mild symptoms that might have been caused by 
age-dependent factors, such as reduced elasticity of the urinary bladder, rather than 
radiation-induced injuries.108,240,250 We set this level at an EPIC score of 80 and 
considered patients with a lower score to have significant symptoms, whereas 
patients with a score over 80 were considered to have trivial symptoms. However, 
even mild symptoms can affect HRQoL, and if such symptoms are caused by late 
radiation-induced injuries, HBOT might be effective, even if the baseline EPIC 
score exceeds 80.240,241,251  
In Paper IV, we defined MID as a change in the EPIC score exceeding 0.5 standard 
deviations of the total baseline EPIC score (MID = 9). This is an established 
method when the clinical assessment of MID is lacking.252 However, MID has 
been specifically assessed for different domains of EPIC and has been found to be 
6–9 for incontinence, 5–7 for irritability and obstruction, and 4–6 for bowel 
symptoms.241 This suggests that we might have underestimated the effects of 
HBOT by setting MID too high in Paper IV. It also lends further support to the 
idea of treating patients with milder symptoms and a score over 80 on EPIC, since 
there is room for improvement for these patients. Furthermore, MID cannot be 
applied on an individual level, since individual baseline values and psychological 
factors impact each patient’s perceived difference in symptoms and their impact 
on HRQoL.253,254  
In RICH-ART, objective findings and underlying mechanisms were also assessed, 
the former via an evaluation by a urologist, and the latter via biopsies taken from 
the urinary bladder. We are not aware of any study on the human urothelium in 
this setting.  
Due to the critique on the external and internal validity of some previous studies, 
noted both in our own HTA analysis and by reviews of the field, we established 
several quality assurance procedures.137,213,255 An e-CRF was created and used for 
data capture during RICH-ART. The study was monitored, had a complete audit 
trial, and had no outstanding queries in the clean file. We believe this ensured the 
quality of the data and the accuracy of the results.  
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5.1.5 WHAT HAPPENS IN THE URINARY BLADDER? – 
PAPER II 
Paper II was designed to assess the effects of HBOT in irradiated urinary bladders 
using a rat model. The rat model has successfully been used in previous 
experiments and has proven to be feasible for assessing radiation-induced 
injuries.256 A small hyperbaric research chamber that could accommodate five rats 
was built for the study.  
The animal study was set up to test the hypothesis that HBOT would reverse the 
radiation-induced responses of oxidative stress and immune activation in the 
urinary bladder. Physiological changes with an increased frequency of micturition 
and a reduced volume of urinary bladder have been assessed in this animal model 
using a similar radiation protocol.257 The time from radiation to HBOT was set to 
14 days, making this a study on sub-acute rather than late radiation-induced 
injuries. It is difficult to make direct comparisons between humans and rats, 
especially when it comes to long-term effects. The cellular turnover rate is higher 
in rats, and they do not develop fibrosis to the same extent as do humans.258,259  
HBOT was given twice daily, to save time, for 10 days. Twice daily HBOT 
treatments for rats have been used before.260 The number of HBOT sessions were 
sufficient to demonstrate a significant result, but future studies may want to 
evaluate the effects after fewer sessions to better understand the dose-dependent 
effects for the results seen in Paper II.  
We assessed the bladders one day after the HBOT protocol was finalized, i.e., 29 
days after irradiation. No major morphological differences were seen between the 
groups. Although rats are less prone to developing fibrosis compared to humans, 
the lack of morphological changes may also be explained by the relatively short 
timeframe between radiation and assessment.250,261 We also assessed angiogenetic 
factors such as HIF1-α and VEGF. HBOT activates and stabilizes HIF1-α, which 
leads to increased cellular proliferation.262 Unpublished data from our group show 
that HBOT may also affect HIF1-α and enhance VEGF expression and 
angiogenesis in irradiated urinary bladders (unpublished data).  
Paper II was conducted at the same time as RICH-ART was including patients. 
The results and experiences from Paper II have been used to further define what 
analyses may be useful regarding biopsies from the urinary bladder taken in the 
RICH-ART study. 
5.1.6 CAN HBOT BE USED PROPHYLACTICALLY? 
HBOT is already used prophylactically before dental extraction in patients with 
osteoradionecrosis in the jaw.2 While this is a form of prophylactic treatment, it 
merely aims to limit the damage of an intrusive procedure in already damaged 
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tissue.263 Paper II shows that some sub-acute changes initiated by irradiation may 
be alleviated by early HBOT before morphological changes are seen. This raises 
the question: Can prophylactic HBOT weeks or months after radiation therapy 
reduce the incidence and severity of late radiation-induced injuries? With the 
reduced incidence of adverse effects, the radiation dose may be increased to 
achieve better cancer treatment results. 
5.1.7 CAN CELLULAR DEATH BE AUGMENTED? – 
PAPER III 
Variables such as dose of radiation, time between radiation and exposure to 
HBOT, the duration of HBOT, the pressure used, and the number of HBOT 
sessions can all be altered and can tentatively produce different effects and 
outcomes. With hundreds of different protocols, we were unable to proceed with 
an animal model. Hence, we examined the feasibility of a cellular model, since 
cellular models allow for studies of specific factors in a well-defined and 
controlled environment. Cellular models can also be adjusted in order to study 
specific pathways.  
The focus was on establishing a model for future cellular experiments in which 
specific effects and pathways involved in irradiation and HBOT can be assessed. 
We used human urothelial and endothelial cells and were able to establish a 
protocol that reversed cellular death in both cell lines. These protocols can be used 
for future studies to assess the dose-dependent effects of radiation and HBOT, as 
well as for studies on specific cellular pathways and mediators.  
5.1.8 RICH-ART IS NOT FINALIZED – BEYOND PAPER IV 
The first part of RICH-ART has been finalized, but apart from a five-year follow-
up, additional data need to be assessed. The control group was offered HBOT 
directly after visit 4. Further analyses of confounding factors will be conducted 
when all patients in the study have completed HBOT. An analysis of biopsies 
concerning oxidative stress, fibrosis, angiogenesis, immunological activity, and 
other factors will also be performed. The five-year follow-up includes yearly 
assessment with EPIC and SF–36, and long-term effects will be assessed when the 
data are available (estimated to be at the end of 2024).  
It would have been desirable to have a longer follow-up for the control group 
before offering HBOT. However, HBOT was a part of clinical practice at most 
centers, and it was considered impossible to withhold the control group HBOT for 
too long. Six months was believed to be sufficient for the effects of HBOT to 
stabilize and allow for natural progression in the control group. The risk of patients 
declining participation increases if the waiting time is too long, with an extension 
to 12 months believed to create problems with inclusion.  
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5.1.9 WHAT IS THE OPTIMAL DOSE OF HBOT? 
As outlined in the introduction (1.5.10), there is little dispute over the optimal 
treatment pressure: 200–250 kPa. This pressure can only be marginally increased 
due to the risk of neurological oxygen toxicity at higher pressures. It is unlikely 
that the desirable effects will be increased at lower pressures, and hence there is 
no need to decrease the treatment pressure.  
Most patients in RICH-ART received 40 sessions of HBOT, but at one center only 
30 sessions were administered. In a preliminary analysis, no differences in the 
primary endpoint were observed between patients treated with 30 and 40 sessions. 
Previous studies have mostly used 30–40 sessions, although some studies have 
used even more.137 The question about dose was coupled with the question about 
responders. Further studies on dose-dependent effects are needed. The value of 
iteration of the treatment months or years after the first session has also been 
poorly investigated.  
5.1.10 WHAT ABOUT SEXUAL FUNCTION? 
Sexual and hormonal function was not assessed. Symptoms from these domains 
are common, and very few studies have assessed the effects of HBOT.264,265 We 
are aware, however, of one study currently being performed with this focus: 
“Hyperbaric Oxygenation Treatment and Quality of Life,” Haukeland University 
Hospital, Bergen, Norway.266 This study is focusing on female patients for whom 
late radiation-induced injuries frequently lead to sexual dysfunction.267,268 This is 
also a common problem for male patients with a history of pelvic radiation 
therapy.240,241 More studies on sexual dysfunction after radiation therapy and the 
use of HBOT are needed.  
5.1.11 IS IT WORTH IT? 
Cost effectiveness is important, since resources are limited. The cost of one HBOT 
elective session is around €200 in Sweden. Visits to the emergency room and costs 
for admission and intervention can easily exceed the cost for a complete HBOT 
protocol. This was illustrated in a study in which the total health care costs for a 
patient with radiation-induced cystitis were compared before and after HBOT.269 
There was a reduction of the yearly health care cost one year after HBOT, even 
when the cost of HBOT was included in the post-treatment total. It therefore seems 
like HBOT can save money by reducing the need for emergency and in-hospital 
care. We have very limited knowledge regarding other costs and potential savings, 
i.e., reduced sick leave. There is also a need for studies that investigate whether 
patients perceive the treatment as “worth it” or not, regardless of the economic 
aspect.256,257 
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5.1.12 LIMITATIONS  
Although enough to generate significant results, the number of included patients 
were small in both clinical papers, 39 patients in Paper I and 79 in Paper IV. This 
limits the level of sub-group analyses that can be made and make analyses of 
confounding factors hard.  
Although included in the study design of RICH-ART, the five-year follow-up has 
not been finalized. Hence it is too early to say anything about long-term effects 
based on the papers in this thesis.  
Adverse events were recorded during HBOT in RICH-ART but was not included 
in the long-term follow-up. We are not aware of any report on increased risk for 
recurrence of cancer or new tumors after HBOT, on the contrary, several reports 
have not found any such link.212,270 However, this aspect needs to be monitored in 
future studies and registries.  
5.1.13 STUDY POPULATION AND ETHICAL 
CONSIDERATIONS 
The study populations in the clinical papers (Paper I and IV) may have been 
affected by doctor’s and patient’s delay or for referral. Also, patients with 
symptoms of late radiation-induced injuries were handled by doctors from 
different specialties. Knowledge of HBOT varied greatly between individual 
doctors, patients, and the general population.136 This might have contributed to the 
selection of patients with more severe symptoms, mainly referred to HBOT from 
urology departments at university hospitals. 
Patients with catheter or other urinary deviations were excluded from RICH–ART. 
This was because the EPIC form contains questions that these patients are unable 
to answer, and hence no valid EPIC score can be calculated.240 However, these 
patients suffer from the same condition as those included in RICH-ART, and it is 
thus reasonable to believe that HBOT will improve patient-perceived symptoms 
in this group of patients as well. Hence, urinary deviation or catheters should not 
be viewed as contraindications for HBOT in late radiation-induced injuries. 
Patients with severe hematuria were also excluded. HBOT without delay was 
considered the standard of care in these severe cases by the urologists.137,209,219 
Hence, it was considered unethical to randomize these patients, which would have 
involved treating one group conservatively. 
We used an animal model in order to assess the effects of HBOT in the irradiated 
urinary bladders of rats. Using smaller animals, such as mice or hamsters, would 
have made it difficult to aim the radiation correctly and would not have provided 
sufficient tissue material for the planned assessments. Using larger animals would 
have required more resources and a larger research hyperbaric chamber. 
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Furthermore, the rat model has already been used and proven to generate both 
microscopical changes and functional impairment.256,257  
5.1.14 A NORDIC HBOT REGISTRY 
Several questions have been raised in the discussion that illustrate future 
perspectives in this field. Some questions may be answered when more data from 
RICH-ART become available, but many others will require new studies. However, 
additional studies can be costly and could require numerous resources. Well-
designed registries can give answers to many of the outstanding questions in this 
field. Prospectively collected data from several centers can be used to evaluate 
confounding factors, effects on sexual function, dose-dependent effects, long-term 
outcomes, etc. The Nordic hyperbaric research group, created for the RICH-ART 
study, already designed an HBOT registry in 2016. It has not yet started data 
collection due to a lack of funding, but it is planning to start the enrollment of 
patients at the end of 2020.  
5.1.15 FINAL REMARKS  
HBOT can alleviate patient-perceived symptoms of late radiation-induced cystitis 
and proctitis and improve HRQoL. HBOT can also reduce macroscopic changes 
of the urinary bladder as well as reverse the oxidative stress and some of the 
downstream effects caused by radiation therapy. The results add further support 
for the efficacy of HBOT for late radiation-induced injuries, which may not only 
help afflicted patients but might also increase the effectiveness of future cancer 
treatments.  
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6 CONCLUSION 
Paper I 
HBOT may be an effective and safe treatment for late radiation-induced soft tissue 
injuries in the pelvic region.  
Paper II  
In an animal model for radiation cystitis, significant elevation of oxidative stress, 
antioxidants, and pro-fibrotic factors were observed, and these were reversed by 
HBOT.  
Paper III 
Cellular death induced by irradiation can be reversed with one session of HBOT 
for UROtsa cells and, in a dose-dependent manner, for HUVEC cells.  
Paper IV 
HBOT is an effective and safe treatment for late radiation-induced cystitis and can 
improve HRQoL.  
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